US20160354375A1 - CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES - Google Patents
CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES Download PDFInfo
- Publication number
- US20160354375A1 US20160354375A1 US15/171,582 US201615171582A US2016354375A1 US 20160354375 A1 US20160354375 A1 US 20160354375A1 US 201615171582 A US201615171582 A US 201615171582A US 2016354375 A1 US2016354375 A1 US 2016354375A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- compound
- aryl
- groups
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *CC.*[Y]C.CC Chemical compound *CC.*[Y]C.CC 0.000 description 7
- OTMSDBZUPAUEDD-UHFFFAOYSA-N CC Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- LCDAQRPNWFQTQU-UHFFFAOYSA-N CC.CC.CCC Chemical compound CC.CC.CCC LCDAQRPNWFQTQU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Definitions
- the invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1 ⁇ ) inhibitors and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
- CK1 ⁇ casein kinase 1 delta
- Alzheimer's disease also known as senile dementia of the Alzheimer type (SDAT), primary degenerative dementia of the Alzheimer's type (PDDAT), or Alzheimer's
- SDAT senile dementia of the Alzheimer type
- PDAT primary degenerative dementia of the Alzheimer's type
- Alzheimer's is the most common form of dementia. Most often, Alzheimer's disease is diagnosed in people over 65 years of age, although the less-prevalent early-onset Alzheimer's can occur much earlier. In 2006, there were 26.6 million sufferers worldwide. Alzheimer's is predicted to affect 1 in 85 people globally by 2050.
- Alzheimer's disease is a neurodegenerative disease characterised by the presence of senile plaques and neurofibrillary tangles in the brain.
- the degree of dementia at death correlates better with neurofibrillary tangle numbers than with senile plaques counts.
- the presence of neurofibrillary tangles in neurons results in the death of those neurons, implying that prevention of tangle formation is an important therapeutic goal.
- the principal protein that forms the neurofibrillary tangle is the microtubule-associated protein, tau, which assembles into filaments that have the appearance of twisting about each other in pairs and are referred to as paired helical filaments (PHF).
- PHF paired helical filaments
- Intraneuronal deposits of tau in the form of typical neurofibrillary tangles of AD or other morphologically distinct tau aggregates in a number of other neurodegenerative diseases is the basis for grouping these conditions as tauopathies.
- the main examples of the tauopathies are frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA).
- the intracellular tau deposits (usually neuronal but can also be glial) are all filamentous and mostly in a hyperphosphorylated state compared to the level of phosphorylation of tau from control human brain. In the case of AD, this hyperphosphorylated tau is often referred to as PHF-tau because it is derived from the PHF.
- Tau is a phosphoprotein, the function of phosphorylation remaining to be unequivocally established.
- increased phosphorylation of tau on multiple serine and threonine residues reduces the ability of tau to promote microtubule assembly and to stabilise assembled microtubules, effects that have been demonstrated both in vitro and in cells.
- Many studies have shown that PHF-tau from AD brain is more heavily phosphorylated on serine and threonine than tau from control brain.
- proline-directed and non-proline directed protein kinases have been suggested to have a role in the generation of PHF-tau in Alzheimer brain, including casein kinase 1.
- Mammalian casein kinase-1 exists as multiple isoforms CK1 ⁇ , CK1 ⁇ , CK1y1, CK1y2, CK1y3, CK1 ⁇ and CK1 ⁇ .
- the role of CK1 ⁇ as a potential tau kinase is of particular interest since it has been reported that CK1 O protein is increased more than 30-fold in the hippocampus of Alzheimer brain compared to equivalent controls (Ghoshal, N. et al (1999) Am. J. Pathol 155, 1163-1172) while its mRNA content is increased 24-fold (Yasojima, K. et al (2000) Brain Res 865, 116-120) and CK1 has also been shown to be tightly associated with PHF (Kuret, J.
- CK1 ⁇ has also been reported to phosphorylate tau at two epitopes detecting using phospho-specific monoclonal antibodies to tau, and exogenous expression of CK1 ⁇ in non-neuronal cells reduces binding of tau to microtubules (Li, G. et al (2004) J. Biol. Chem. 279, 15938-15945).
- A( ⁇ ) amyloid beta-peptide
- CK1 ⁇ inhibitors which may be of potential therapeutic benefit in the treatment of neurodegenerative diseases, such as tauopathies including Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA).
- tauopathies including Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA).
- a pharmaceutical composition comprising a compound of formula (IA) or a pharmaceutically acceptable salt or solvate thereof:
- Het A represents a 4 or 5 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
- X and Y independently represent a bond, —C(R 7a )(R 8a )—,(CH 2 ) 2 , —O—, —S—, —CH 2 —O—, —(CH 2 ) 2 —O—, NR 6a , —N(R 6a )—C(R 7a )(R 8a )—, —N(R 6a )—(CH 2 ) 2 —, —N(R 6a )—(CH 2 ) 3 —, —CH 2 —N(R 6a )—(CH 2 ) 2 —, —N(R 6a )—CO—, —CH
- R 4a represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, —O—C 1-6 alkenyl, haloC 1-6 alkoxy, —COOH, —CO—C 1-6 alkyl, —COO—C 1-6 alkyl, —CONH 2 , —CH 2 —CONH 2 , —NH—C 1-6 alkyl, —NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO—C 1-6 alkyl,
- the compound of formula (IA) is selected from any of compounds: 1, 4-17, 19-25, 36-37, 39-40, 42, 44-45, 52, 61, 71-76, 80-83, 86-91, 93-97, 102-107, 110-112, 114, 117-122, 139-143, 149-151, 153, 158-160, 163-170, 174-177, 185-197, 200, 202-203,208-209, 211, 213-221, 223-224, 226, 228-229, 232, 234, 237-240, 256, 261-264, 267-268, 270, 272, 275-283, 296, 304, 313, 319, 321-323, 326-328, 332, 334-335, 342-345, 350, 356, 361-365, 367-369, 372, 377, 379, 383, 393, 398, 403, 406, 412-413, 416-423, 431-432, 434, 436, 438-440
- the compound of formula (IA) is selected from any of compounds: 5-6, 9-11, 16-17, 19-20, 23-25, 37, 39-40, 42, 44-45, 52, 71, 73, 76, 80-83, 86-87, 89, 91, 93-94, 96-97, 102, 104-106, 111-112, 114, 117-122, 139-143, 149-151, 153, 159, 164, 166, 168, 174-177, 185-187, 190, 192, 195-197, 202-203, 208-209, 211, 214-221, 223-224, 226, 228-229, 232, 234, 237-238, 240, 261-264, 267, 270, 275-283, 313, 319, 321-322, 327-328, 332, 334-335, 342-345, 350, 361-365, 367, 369, 372, 377, 379, 383, 393, 3
- the compound of formula (IA) is selected from any of compounds:
- the compound of formula (IA) is selected from any of compounds: 10, 45, 240, 654, 656, 766 and 856 as described herein or a pharmaceutically acceptable salt or solvate thereof, such as compounds 10, 654 and 856.
- the compound of formula (IA) is selected from any of compounds: 10, 25, 42, 45, 223, 240, 281-282, 321, 439, 465, 506, 512, 611-614, 619, 623-624, 633, 639, 654, 656, 670, 672, 676-677, 683, 697, 717, 736, 761, 765-766, 768, 809-810, 820, 842, 851, 856, 859-860, 863, 931, 947-948, 967, 970, 982, 984, 989, 991-992, 1000 and 1002 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compounds of this embodiment were tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 5%.
- the compound of formula (IA) is selected from any of compounds:
- the compound of formula (IA) is selected from any of compounds: 10, 654, 856, 859, 931 and 947 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compounds of this embodiment were tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 90%.
- composition comprising a compound of formula (IB) or a pharmaceutically acceptable salt or solvate thereof:
- Het B represents a 5 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
- Z represents a bond, —C(R 7b )(R 8b )—, (CH 2 ) 2 , —O—, —S—, —CH 2 —O—, —(CH 2 ) 2 —O—, NR 6b , —N(R 6b b)—C(R 7b )(R 8b )—, —N(R 6b )—(CH 2 ) 2 —, —N(R 6b )—(CH 2 ) 3 —, —CH 2 —N(R 6b )—(CH 2 ) 2 —, —N(R 6b )—OO—, —CH 2 —NH—CO—
- R 4b represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, alkenyl, haloC 1-6 alkoxy, —COOH, —CO—C 1-6 alkyl, —COO—C 1-6 alkyl, —CONH 2 , —CH 2 —CONH 2 , —NH—C 1-6 alkyl, —NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO 2 —C 1-6 alkyl, —SO 2 —
- the compound of formula (IB) is selected from any of compounds 2-3, 26-28, 30-33, 35, 47-48, 51, 57-60, 63-64, 78, 84, 113, 123, 127-129, 145, 155-157, 171-173, 204, 206-207, 210, 225, 227, 233, 235-236, 241-242, 244, 249, 269, 285, 288, 303, 307-312, 314-316, 320, 324-325, 333, 336, 351, 357-360, 374-375, 384-391, 396, 399-402, 404-405, 407-411, 414, 424-425, 427-428, 437, 448, 456-457, 482, 484-485, 489-491, 495, 497-498, 505, 507, 516, 519, 524, 526, 553, 559-560, 568, 570, 575, 609, 615-616
- the compound of formula (IB) is selected from any of compounds: 2-3, 26-28, 30, 32-33, 47-48, 51, 59-60, 84, 113, 123, 127, 129, 145, 155, 157, 172-173, 204, 206-207, 210, 225, 233, 235-236, 241, 244, 269, 285, 288, 307-311, 315-316, 320, 324-325, 333, 336, 351, 357-360, 374-375, 385-386, 388-391, 396, 399-402, 404-405, 407-410, 414, 424, 427-428, 437, 457, 482, 490, 495, 497-498, 505, 516, 519, 553, 559- 560 and 568 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (IB) is selected from any of compounds:
- the compound of formula (IB) is selected from any of compounds:
- a pharmaceutical composition comprising a compound of formula (IC) or a pharmaceutically acceptable salt or solvate thereof:
- Het C represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
- X c and Y c independently represent a bond, —C(R 7c )(R 8c )—, (CH 2 ) 2 , —O—, —S—, —CH 2 —O—, —(CH 2 ) 2 —O—, NR 6c , —N(R 6c )—C(R 7c )(R 8c )—, —N(R 6c )—(CH 2 ) 2 —, —N(R 6c )—(CH 2 ) 3 —, —CH 2 —N(R 6c )—(CH 2 ) 2 —, —N(R 6c )—CO—,
- R 4c groups represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, —O—C 1-6 alkenyl, haloC 1-6 alkoxy, —COOH, —COO—C 1-6 alkyl, —COO—C 1-6 alkyl, —CONH 2 , —CH 2 —CONH 2 , —NH—C 1-6 alkyl, —NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —S—C 1-6 alkyl
- R 4c groups and wherein said C 1-6 alkyl groups of R 3c may be optionally substituted by one or more hydroxyl groups; with the proviso that the compound is other than compound number 161, 648, 658, 680, 726, 824, 867, 880, 892, 896, 901, 903, 906, 928 and 944.
- Het C represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to one further ring to form a bicyclic ring system.
- Het C represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to a phenyl ring to form a bicyclic ring system.
- Het C represents a 6 membered heterocyclic ring system containing 1 or 2 nitrogen atoms, wherein said ring system is optionally fused to a phenyl ring to form a bicyclic ring system.
- Het C represents pyridinyl, pyrimidinyl or quinazolinyl.
- Het C represents quinazolinyl.
- X c and Y c independently represent a bond or NR 6c . In a further embodiment, X c and Y c independently represent a bond or NH. In a yet further embodiment, one of X c and Y c represents a bond and the other represents a bond or NH. In a yet further embodiment, one of X c and Y c represents a bond and the other represents NH.
- R 1c and R 2c independently represent aryl, bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R 1c and R 2c may be substituted by one or more (e.g. 1, 2 or 3) R 4c groups.
- R 1c and R 2c independently represent aryl (e.g. phenyl), bicyclic heterocyclyl (e.g. benzodioxinyl), monocyclic heteroaryl (e.g. pyridinyl, pyrazolyl or thiophenyl) or bicyclic heteroaryl ring system (e.g.
- R 1c and R 2c may be substituted by one or more (e.g. 1, 2 or 3) R 4c groups.
- R 1c and R 2c independently represent aryl (e.g. phenyl), bicyclic heterocyclyl (e.g. benzodioxinyl), monocyclic heteroaryl (e.g. pyridinyl, pyrazolyl or thiophenyl) or bicyclic heteroaryl ring system (e.g. benzoxazolyl), wherein R 1c and R 2c may be substituted by one or more (e.g. 1) R 4c groups selected from hydroxyl, C1 -6 alkoxy (e.g. methoxy) or —CONH 2 .
- R 1c and R 2c independently represent aryl (e.g. phenyl) or monocyclic heteroaryl (e.g. pyridinyl, pyrazolyl or thiophenyl) wherein R 1c and R 2c may be substituted by one or more (e.g. 1) R 4c groups selected from hydroxyl, C 1-6 alkoxy (e.g. methoxy) or —CONH2.
- R 1c and R 2c independently represent unsubstituted aryl (e.g. phenyl) or unsubstituted monocyclic heteroaryl (e.g. pyridinyl or pyrazolyl).
- one of R 1c and R 2c represents unsubstituted aryl (e.g. phenyl) and the other represents unsubstituted monocyclic heteroaryl (e.g. pyridinyl or pyrazolyl).
- aryl e.g. phenyl
- monocyclic heteroaryl e.g. pyridinyl or pyrazolyl
- p represents an integer from 0 to 2. In one embodiment, p represents 0. In an alternative embodiment, p represents 1. In an alternative embodiment, p represents 2.
- R 3c represents ⁇ O, cyano or a monocyclic heteroaryl ring system (e.g. pyridinyl).
- R 3c represents a monocyclic heteroaryl ring system (e.g. pyridinyl).
- R 3c when p represents 2, R 3c represents ⁇ O and cyano.
- the compound of formula (IC) is selected from any of compounds:
- the compound of formula (IC) is selected from any of compounds: 46, 147, 294-295, 329, 341, 435, 486, 520, 539, 542-543, 547-549, 556 and 567 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (IC) is selected from any of compounds:
- the compound of formula (IC) is selected from any of compounds: 567, 631, 640, 661, 668, 700, 727, 823, 868, 870, 888-890, 894, 946, 949-951, 953, 957, 973, 977, 981, 983, 985-986, 993 and 995 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compounds of this embodiment were tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 5%.
- the compound of formula (IC) is selected from any of compounds:
- the compound of formula (IC) is selected from any of compounds:
- the compound of formula (IC) is selected from any of compounds:
- a pharmaceutical composition comprising a compound of formula (ID) or a pharmaceutically acceptable salt or solvate thereof:
- Het D represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
- Z d represents a bond, —C(R 7d )(R 8d )—, —(CH 2 )—C(R 7d )(R 8d )—, —O—, —S—, —CH 2 —O—, —(CH 2 ) 2 —O—, NR 6d , —N(R 6d )—C(R 7d )(R 8d )—, —N(R 6d )—(CH 2 ) 2 —, —N(R 6d )—(CH 2 ) 3 —, —CH 2 —N(R 6d )—(CH 2 ) 2 —, —N(R 6d
- R 4d represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy alkoxy, —COOH, —CO—C 1-6 alkyl, —COO—C 1-6 alkyl, —CONH 2 , —CH 2 —CONH 2 , —NH—C 1-6 alkyl, —NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO 2 —C 1-6 alkyl, —SO 2 —C 1-6 alkyl, —SO 2
- the compound of formula (ID) is selected from any of compounds: 29, 34, 41, 65-70, 92, 109, 116, 126, 130-137, 162, 182, 231, 246, 252-255, 258, 274, 290-293, 297-298, 317-318, 330-331, 347-349, 352, 450-454, 483, 536-538, 545, 550, 564-565, 572, 620, 637, 655, 663, 675, 682, 686, 691, 696, 706, 711, 724, 728-729, 737, 744-745, 748, 752, 774-776, 781, 797-799, 832, 834, 954, 958, 964-965, 971, 974-976, 978-980, 994 and 997-998 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (ID) is selected from any of compounds: 34, 41, 65-66, 68-69, 109, 126, 130, 132-137, 162, 182, 231, 246, 252-255, 258, 274, 290, 293, 297-298, 317-318, 348-349, 352, 450-453, 536, 545, 550, 564-565 and 572 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (ID) is selected from any of compounds:
- the compound of formula (ID) is selected from any of compounds: 663, 675, 682, 696, 706, 737, 748, 797, 832, 834, 954, 958, 964-965, 971, 974-976, 978980, 994 and 997-998 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compounds of this embodiment were tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 5%.
- the compound of formula (ID) is selected from any of compounds: 682, 954, 964, 978-979 and 997 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compounds of this embodiment were tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 50%.
- a pharmaceutical composition comprising a compound of formula (1E) or a pharmaceutically acceptable salt or solvate thereof:
- Het E represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S;
- Z e represents a bond, —C(R 7e )(R 8e )—, (CH 2 ) 2 , —O—, —S—, —CH 2 —O—, —(CH 2 ) 2 —O—, NR 6e , —N(R 6e )—C(R 7e )(R 8e )—, —N(R 6e )—(CH 2 ) 2 —, —N(R 6e )—(CH 2 ) 3 —, —CH 2 —N(R 6e )—(CH 2 ) 2 —, —N(R 6e )—CO—, —CH 2 —NH—CO—(CH 2 ) 2 —, —N(R 6e )—CO—CH 2 —, —CO—N(R 6e )—CH 2
- R 4e groups represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, alkenyl, haloC 1-6 alkoxy, —COOH, —CO—C 1-6 alkyl, —COO—C 1-6 alkyl, —CONH 2 , —SO 2 NH 2 , —CH 2 —CONH 2 , —NH—C 1-6 alkyl, —NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —NH—NH 2 , —O—CH 2 —CO—NH—C 1-6 alkyl, —CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—
- the compound of formula (IE) is selected from any of compounds:
- the compound of formula (IE) is selected from any of compounds: 18, 62, 115, 146, 148, 222, 230, 251, 265, 300, 306, 338, 346, 381, 392, 426, 561 and 583 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (IE) is selected from any of compounds:
- the compound of formula (IE) is selected from any of compounds: 583, 646, 660, 723, 730, 780, 822, 830, 885-886, 941, 966 and 988 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compounds of this embodiment were tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 5%.
- a pharmaceutical composition comprising a compound of formula (IF) or a pharmaceutically acceptable salt or solvate thereof:
- Het F represents a heterocyclic ring system containing 1 to 3 heteroatoms selected from 0, N or S, wherein said ring system is fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
- R 1f represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl hydroxyl, C 1-6 alkoxy, —O—C 1-6 alkenyl, haloC 1-6 alkoxy, —COOH, —CO—C 1-6 alkyl, —COO—C 1-6 alkyl, —CONH 2 , —CH 2 —CONH 2 , —NH—C 1-6 alkyl, —NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH
- the compound of formula (IF) is selected from any of compounds: 53, 79, 124-125, 205, 289, 299, 301-302, 353-355, 397, 500 and 511 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (IF) is selected from any of compounds: 79, 125, 205, 289, 299, 301-302, 353-355, 397, 500 and 511 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (IF) is Compound 205 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of this embodiment was tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 50%.
- a pharmaceutical composition comprising a compound of formula (IG) or a pharmaceutically acceptable salt or solvate thereof:
- Z g represents a bond, —C(R 7g )(R 8g )—, (CH 2 ) 2 , —O—, —S—, —CH 2 —O—, —(CH 2 ) 2 —O—, NR 6g , —N(R 6g )—C(R 7g )(R 8g )—, —N(R 6g )—(CH 2 ) 2 —, —N(R 6g )—(CH 2 ) 3 —, —CH 2 —N(R 6g )—(CH 2 ) 2 —, —N(R 6g )—CO—, —CH 2 —NH—CO—(CH 2 ) 2 —, —N(R 6g )—CO—CH 2 —, ⁇ N—, —C(H)(CN)—, —C( ⁇ N—NH—COC 1-6 alkyl)-, —CH ⁇ C(R 6g )—,
- R 4g groups represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, haloC 1-6 alkoxy, —COOH, —CO—C 1-6 alkyl, —COO—C 1-6 alkyl, —CONH 2 , —CH 2 —CONH 2 , —NH—C 1-6 alkyl, —NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO 2 —C 1-6 alkyl, —SO 2 —C 1-6 al
- the compound of formula (IG) is selected from any of compounds: 98-101, 248, 257, 259-260, 266, 271, 380, 394, 449, 461, 464, 477, 502-504, 523, 530, 535, 574, 673, 713, 779, 788, 825, 881-882, 935, 956, 968, 972 and 996 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (IG) is selected from any of compounds:
- the compound of formula (IG) is compound 825 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (IG) is selected from any of compounds: 825, 881-882, 935, 956, 968, 972 and 996 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compounds of this embodiment were tested in the CK1 O inhibition assay as described herein and exhibited inhibition of greater than 5%.
- the compound of formula (IG) is Compound 972 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- the compound of this embodiment was tested in the CK1O inhibition assay as described herein and exhibited inhibition of greater than 50%.
- a pharmaceutical composition comprising a compound of formula (IH) or a pharmaceutically acceptable salt or solvate thereof:
- Het H1 and “Het H2” independently represent a 5 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S;
- Z h represents a bond, —C(R 7h )(R 8h )—, (CH 2 ) 2 , —O—, —S—, —CH 2 —O—, —(CH 2 ) 2 —O—, NR 6h , —N(R 6h )—C(R 6h )(R 7h )—, —N(R 6h )—(CH 2 ) 2 —, —N(R 6h )—(CH 2 ) 3 —, —CH 2 —N(R 6h )—(CH 2 ) 2 —, —N(R 6h )—CO—, —CH 2 —NH—CO—(CH 2 ) 2 —, —N(R 6h )—CO—CH 2 —, ⁇ N—
- the compound of formula (IH) is selected from any of compounds:
- salts are intended to indicate salts which are not harmful to the patient.
- Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts and pharmaceutically acceptable akaline addition salts.
- Acid addition salts include salts of inorganic acids as well as organic acids.
- suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
- suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like.
- compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
- metal salts include lithium, sodium, potassium, magnesium salts and the like.
- ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
- alkaline salts include, for example, sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine, N-methylglucamine.
- bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzyl
- the compounds of formulae (IA)-(IH) can be in racemic forms, as well as in the form of pure enantiomers or non racemic (scalemic) mixture of enantiomers, including when the compounds of formulae (IA)-(IH) have more than one stereogenic centre.
- halogen means a fluorine, chlorine, bromine or iodine atom.
- C 1-6 alkyl means any linear, branched hydrocarbon groups having 1 to 6 carbon atoms, or cyclic hydrocarbon groups having 3 to 6 carbon atoms.
- Representative examples of such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, n-pentyl, isopentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- References to “haloC 1-6 alkyl” mean a C 1-6 alkyl group substituted by one or more halogen atoms as herein defined.
- C 1-6 alkylene means a saturated divalent hydrocarbon chain having the specified number of member atoms.
- C 1-6 alkylene refers to a bond or an alkylene group having from 1 to 6 member atoms.
- Alkylene groups may be straight or branched. Representative branched alkylene groups have one or two branches.
- Alkylene includes methylene, ethylene, propylene (n-propylene and isopropylene) and butylene (n-butylene, isobutylene, and t-butylene).
- C 2-6 alkenyl means any linear, branched hydrocarbon groups of 2 to 6 carbon atoms, or cyclic hydrocarbon group having 3 to 6 carbon atoms having at least one double bond.
- alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl.
- C 2-6 alkynyl means any linear, or branched hydrocarbon groups of 2 to 6 carbon atoms, having at least one triple bond.
- Representative examples of such alkynyl groups include ethynyl, propargyl and butynyl.
- C 1-6 alkoxy means an —O—C 1-6 alkyl group wherein C1-6 alkyl is as defined herein. Examples of such groups include methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy and the like.
- C 3-8 cycloalkyl means a saturated monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl and the like.
- aryl means a C 6-12 monocyclic or bicyclic hydrocarbon ring wherein at least one ring is aromatic. Examples of such groups include phenyl, indyl or naphthyl and the like.
- heteroatom means a nitrogen, sulphur, or oxygen atom.
- heterocyclyl means a saturated or unsaturated non-aromatic ring containing from 1 to 4 heteroatoms as member atoms in the ring. Heterocyclyl groups containing more than one heteroatom may contain different heteroatoms. Heterocyclyl groups may be optionally substituted with one or more substituents as defined herein. Heterocyclyl groups are monocyclic ring systems or fused bicyclic or polycyclic ring systems or bicyclic structures known as heterocyclic “Spiro” ring systems. In certain embodiments, heterocyclyl is saturated. In other embodiments, heterocyclyl is unsaturated and non-aromatic.
- Non-limiting examples of monocyclic heterocyclyl ring systems include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, pyranyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothienyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-oxathiolanyl, 1 ,3-oxathianyl, 1,3-dithianyl, and azetidinyl.
- heteroaryl means an aromatic ring containing from 1 to 4 heteroatoms as member atoms in the ring. Heteroaryl groups containing more than one heteroatom may contain different heteroatoms. Heteroaryl groups may be optionally substituted with one or more substituents as defined herein. Heteroaryl groups are monocyclic ring systems or are fused bicyclic or polycyclic ring systems. Monocyclic heteroaryl rings have 5 or 6 member atoms. Bicyclic heteroaryl rings have from 7 to 11 member atoms.
- Bicyclic heteroaryl rings include those rings wherein phenyl and a monocyclic heterocyclyl ring are attached forming a fused bicyclic ring system, and those rings wherein a monocyclic heteroaryl ring and a monocyclic cycloalkyl, cycloalkenyl, heterocyclyl, or heteroaryl ring are attached forming a fused bicyclic ring system.
- heteroaryl includes pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furanyl, furazanyl, thienyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, indolyl, isoindolyl, indolizinyl, indazolyl, purinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pteridinyl, cinnolinyl, benzimidazolyl, benopyranyl, benzoxazolyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzothienyl, furopyridinyl, and
- heterocyclic ring system mean either a heterocyclyl ring system or a heteroaryl ring system as hereinbefore defined.
- Representative compounds of the invention include compounds 1-1002 as set forth below:
- composition comprising any one of the compounds of formulae (IA)-(IH) for use in the treatment of a neurodegenerative disorder, such as tauopathies.
- compositions of the invention may comprise, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those of ordinary skill in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those of ordinary skill in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- the precise nature of the carrier or other material may depend on the route of administration, e. g., oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.
- compositions for oral administration may be in tablet, capsule, powder or liquid form.
- a tablet may include a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil.
- a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil.
- Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
- the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
- Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
- the compounds of formulae (IA)-(IH) are believed to be casein kinase 1 delta (CK1 ⁇ ) inhibitors.
- Certain compounds of formulae (IA)-(IH) have inhibitory activity of greater than 5%, in particular greater than 10%, more particularly greater than 25%, yet more particularly greater than 50%, especially greater than 75%, such as greater than 90%.
- Such compounds may be useful in the treatment in neurodegenerative disorders such as tauopathies.
- Tauopathies are conditions which are characterised by neurofibrillary tangles or aggregates of the tau protein.
- Tauopathies are a recognised class of conditions known to those skilled in the art and include Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, multisystem atrophy (MSA), neurobasal degeneration with iron accumulation, type 1 (Hallervorden-Spatz), argyrophilic grain dementia, Down's syndrome, diffuse neurofibrillary tangles with calcification, dementia pugilistica, Gerstmann-Straussler-Scheinker disease, myotonic dystrophy, Niemann-Pick disease type C, progressive subcortical gliosis, prion protein cerebral amyloid angiopathy, tangle only dementia, postencephalitic parkinsonism, subacute sclerosing panencephalitis, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis/parkinsonism-dementia complex
- the intracellular tau deposits are usually neuronal or glial and are filamentous and generally in a hyperphosphorylated state as compared to the level of phosphorylation in tau from control human brain.
- this hyperphosphorylated tau is often referred to a paired helical filament tau (PHF) tau because it is derived from the PHF.
- the tauopathy comprises Alzheimer's disease.
- a method of treating a neurodegenerative disorder such as tauopathies, which comprises administering a therapeutically effective amount of a compound of formulae (1A)-(1 H).
- CK1 ⁇ Inhibition Assay The compounds of the invention may be tested for inhibition of casein kinase 1 delta (CK1 ⁇ ) in accordance with the assay protocols described in US 2010/0152157, EP 1,636,375 or Hanger et al (2007) J. Biol. Chem. 282, 23645-23654. In particular, the assay was conducted in accordance with the following protocol:
- Base Reaction buffer 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO
- Recombinant human full-length construct GST-tagged, expressed in insect cells.
- compounds 10, 324, 654, 856, 859, 931, 947, 952, 987, 990 and 999 exhibited inhibition of greater than 90%.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
Description
- This application is a divisional application that claims priority to U.S. application Ser. No. 13/993,288 filed on Sep. 19, 2013, which is the U.S. national stage entry of International Patent Application No. PCT/GB2011/052475 filed on Dec. 14, 2011, which claims priority to GB Application No. 1109162.6 filed on Jun. 1, 2011 and GB Application No. 1021161.3 filed on Dec. 14, 2010, the entire contents of each of which is incorporated herein by reference in their entireties.
- The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) inhibitors and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
- Alzheimer's disease (AD; also known as senile dementia of the Alzheimer type (SDAT), primary degenerative dementia of the Alzheimer's type (PDDAT), or Alzheimer's) is the most common form of dementia. Most often, Alzheimer's disease is diagnosed in people over 65 years of age, although the less-prevalent early-onset Alzheimer's can occur much earlier. In 2006, there were 26.6 million sufferers worldwide. Alzheimer's is predicted to affect 1 in 85 people globally by 2050.
- Alzheimer's disease is a neurodegenerative disease characterised by the presence of senile plaques and neurofibrillary tangles in the brain. The degree of dementia at death correlates better with neurofibrillary tangle numbers than with senile plaques counts. The presence of neurofibrillary tangles in neurons results in the death of those neurons, implying that prevention of tangle formation is an important therapeutic goal. The principal protein that forms the neurofibrillary tangle is the microtubule-associated protein, tau, which assembles into filaments that have the appearance of twisting about each other in pairs and are referred to as paired helical filaments (PHF). PHF are present in different locations in degenerating neurons in the Alzheimer brain and when many aggregate in the neuronal cell body, they produce the neurofibrillary tangle (Lee et al, 2001).
- Intraneuronal deposits of tau in the form of typical neurofibrillary tangles of AD or other morphologically distinct tau aggregates in a number of other neurodegenerative diseases, is the basis for grouping these conditions as tauopathies. Thus, in addition to AD, the main examples of the tauopathies are frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA). The intracellular tau deposits (usually neuronal but can also be glial) are all filamentous and mostly in a hyperphosphorylated state compared to the level of phosphorylation of tau from control human brain. In the case of AD, this hyperphosphorylated tau is often referred to as PHF-tau because it is derived from the PHF.
- Tau is a phosphoprotein, the function of phosphorylation remaining to be unequivocally established. However, increased phosphorylation of tau on multiple serine and threonine residues reduces the ability of tau to promote microtubule assembly and to stabilise assembled microtubules, effects that have been demonstrated both in vitro and in cells. Many studies have shown that PHF-tau from AD brain is more heavily phosphorylated on serine and threonine than tau from control brain. This has been demonstrated partly by protein sequencing and partly by demonstrating that certain monoclonal antibodies only label either PHF-tau or non-phosphorylated tau and not PHF-tau; the epitopes for many of these antibodies have been mapped to particular phosphorylated residues present in PHF-tau and absent from control brain tau. The pathological tau from most other cases of other tauopathies seems to be similarly hyperphosphorylated to PHF-tau.
- These findings strongly imply that similar abnormalities in regulating phosphorylation of tau are shared by all the tauopathies including AD.
- A number of proline-directed and non-proline directed protein kinases have been suggested to have a role in the generation of PHF-tau in Alzheimer brain, including casein kinase 1.
- Mammalian casein kinase-1 exists as multiple isoforms CK1α, CK1β, CK1y1, CK1y2, CK1y3, CK1δ and CK1ε. The role of CK1δ as a potential tau kinase is of particular interest since it has been reported that CK1 O protein is increased more than 30-fold in the hippocampus of Alzheimer brain compared to equivalent controls (Ghoshal, N. et al (1999) Am. J. Pathol 155, 1163-1172) while its mRNA content is increased 24-fold (Yasojima, K. et al (2000) Brain Res 865, 116-120) and CK1 has also been shown to be tightly associated with PHF (Kuret, J. et al (1997) J. Neurochem 69, 2506-2515). CK1δ has also been reported to phosphorylate tau at two epitopes detecting using phospho-specific monoclonal antibodies to tau, and exogenous expression of CK1δ in non-neuronal cells reduces binding of tau to microtubules (Li, G. et al (2004) J. Biol. Chem. 279, 15938-15945). Of note in the context of Alzheimer's disease is a report that CK1 activity is stimulated by amyloid beta-peptide (A(β), a component of the senile neuritic plaques that, together with tangles, characterise Alzheimer brain (Chauhan, A. et al (1993) Brain Res. 629, 47-52). Additional evidence for possible involvement of CK1 in Alzheimer's disease comes from the reported influence of CK1 in the regulation of Aβ production in neurons (Flajolet, M. et al (2007) PNAS USA 104, 4159-4164). Further work has confirmed that at least 6 newly identified phosphorylation sites in PHF-tau (all on serine or threonine residues) can be generated by CK1δ. The finding that a number of phosphorylation sites in PHF-tau for which CK1 is a strong candidate kinase, including three for which it is the only known kinase, implies that CK1 may make an important contribution to the pathogenesis of Alzheimer's disease (Hanger et al (2007) J. Biol. Chem. 282, 23645-23654).
- There is therefore a need for CK1δ inhibitors which may be of potential therapeutic benefit in the treatment of neurodegenerative diseases, such as tauopathies including Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA).
- According to a first aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (IA) or a pharmaceutically acceptable salt or solvate thereof:
- wherein
“Het A” represents a 4 or 5 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings; X and Y independently represent a bond, —C(R7a)(R8a)—,(CH2)2, —O—, —S—, —CH2—O—, —(CH2)2—O—, NR6a, —N(R6a)—C(R7a)(R8a)—, —N(R6a)—(CH2)2—, —N(R6a)—(CH2)3—, —CH2—N(R6a)—(CH2)2—, —N(R6a)—CO—, —CH2—NH—CO—(CH2)2—, —N(R6a)—CO—CH2—, —N(R6a)—OO—(CH2)2—, —CO—N(R6a)—CH2—, ═N—, —C(H)(CN)—, —C(═N—NH—COC1-6 alkyl)-, —CH═C(R6a)—OO—, ═CH—, —CH═CH—, ═CH—CO—, —N═CH—, —N═C(Me)—, —C(R6a)═CH—, —NH—N═C(H)—, —NH—CO—C(═CH-heteroaryl)-, —C═C(Me)2—, —CH═CH—CO—N(R6a)—, —CH═C(R6a)—NH—CO—, —CH═C(R6a)—C—O—CH2—, —CS—S—CH2—, —NH—CS—NH—, —NH—CS—NH—CH2—, —NH—CS—NH—(CH2)2—, —CH2—N(CSNH2)—CH2—, —S—CH2—, —S—CH2—, —S—(CH2)2—O—, SO2, —NH—SO2—, —CH2—N(R6a)—SO2—, CO, —CH2—CO—, —(CH2)2—CO—, —O—CH2—CO—, —(CH2)2—CO—, COO, —COO—C(R7a)CO—, —CH═C(R5a)—CONH—CH2—, —CO—CH2—N(R6a)—CO—, —CO—CH2—C(R6a)—CH2—CO—, —CO—CH2N(R6a)—CH2—, —CO—NH—N═C(R7a)—, —S—CH2—CO—, —S—CH2—CO—N(R6a)—, —S—CH2—CO—N(R6a)—CH2—, —SO2—N(R6a)—C(R7a)(R8a) —CONH—, —SO2—N(R6a)—CH(—CH2-aryl)-CONH—CH2—, —CH(—S—C1-6 alkyl)—C(Me)(OH)—, —CH2—C(R6a)(OH)—, —C(OH)(CH(Me)(C3-8 cycloalkyl))-CH2—, —C(OH)(R6a)—CH2—, —CH(Me)—NH—CO—CH2—, —CO—N(R6a)—CH2—, —CO—N(R6a)—CH2—CH2—, —CO—(R6a)—CH2—CH2—CO—NH—CH2—, —CO—NH—C(—CONH2)═CH—, —CO—NH—CH(—CONH2)—CH2—, —CH2—C(H)(Me)—CH2—S—, —O—CH2—CO—NH—, —CH2—N(R6a)—CO—CH2—O—, —N(R6a)—CO—CH2—O—, —C(H)(—CH2-aryl)-, —C(H)(—CH2-heteroaryl)-, —C(NH-aryl)=N—N═CH—, —C(NH-aryl)=N—N═CH—, —NH—N═C(-aryl)-, —NH—N═C(-aryl)-CO—, —NH—C(═N—CO—C1-6 alkyl)-NH—(CH2)2—, —C(—NH-aryl)=N—N═CH—, —NH—C(—NH-aryl)=N—CONH—, —C(═CH-aryl)-CONH—CH2—, —CH═C(R6a)—CONH—, —CH(—CH2-aryl)-NH—CO— or —CH(OH)—,
wherein said aryl or heteroaryl groups of X and Y may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, NO2 or hydroxyl groups;
R5a represents hydrogen, C1-6 alkyl or cyano;
R6a represents hydrogen, C1-6 alkyl, C1-6 alkoxy, cyano, C3-8 cycloalkyl, —CH2—C3-8 cycloalkyl, aryl, heteroaryl, —C1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R7a)(R8a)-heteroaryl, wherein said aryl groups of R6a may be optionally substituted by one or more halogen or C1-6 alkoxy groups;
R7a and R8a independently represent hydrogen or C1-6 alkyl;
R1a and R2a independently represent aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R1a and R2a may be substituted by one or more (e.g. 1, 2 or 3) R4a groups;
R4a represents halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C3-8 cycloalkyl, haloC1-6 alkyl, hydroxyl, C1-6 alkoxy, —O—C1-6 alkenyl, haloC1-6 alkoxy, —COOH, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —CONH2, —CH2—CONH2, —NH—C1-6 alkyl, —NH—C2-6alkenyl, —NH—CO—C1-6 alkyl, —CO—NH—C1-6 alkyl, —O—CH2—CO—NH—C1-6 alkyl, —CH2—CH2—CO—NH—C1-6 alkyl, —S—C1-6 alkyl, —SO—C1-6 alkyl, —SO2—C1-6 alkyl, —SO2—NH—C1-6 alkyl, —S—CH2—CO—C2-6alkenyl, —SO2—OH, amino, cyano, NO2, ═O, —CO—NH—(CH2)2)—OMe, —NH—C3-8 cycloalkyl, —CO-heterocyclyl, —CO-aryl, —CO-heteroaryl, —COO—(CH2)2-heterocyclyl, —OCH2-aryl, —OCH2-heteroaryl, —CH2—O—CO-aryl, —O-aryl, —NH—CO-heteroaryl, —NH—CO—CH2-aryl, —NH-aryl, —NH—SO2-aryl, aryl or heteroaryl groups, wherein said aryl, heterocyclyl or heteroaryl groups of R4a may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, ═S or hydroxyl groups and wherein said C1-6 alkyl or C2-6 alkenyl groups of R4a may be optionally substituted by one or more hydroxyl, amino, cyano,
C1-6 alkoxy, CONH2 or —COO—C1-6 alkyl groups;
n represents an integer from 0 to 3;
R3a represents halogen, haloC1-6 alkyl, C1-6 alkyl, hydroxyl, C1-6 alkoxy, —S—C1-6 alkyl, —CH2—S—C1-6 alkyl, —S—C2-6 alkynyl, amino, cyano, NO2, ═O, ═S, —SO2—C1-6alkyl, —CONH2, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —NH—C1-6 alkyl, —NH—CO—C1-6 alkyl, —NH—CO—CH═CH—CH2—N(Me)2, C1-6 alkyl, —CO—NH—C1-6 alkyl, —CO—NH—CH(Me)—COOH, —S—CH2—CO—N(Et)2, —NH—(CH2)2—OH, —NH—(CH2)3—OH, —NH—CH(Et)—CH2—OH, —CO—NH—(CH2)3—OH, —CH(CH2OH)2 or —S—CH2—CO—NH—CO—NH—Cl1-6 alkyl, aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein said aryl, heterocyclyl or heteroaryl groups of R3a may be optionally substituted by one or more (e.g. 1, 2 or 3) R4a groups and wherein said C1-6 alkyl groups of R3a may be optionally substituted by one or more hydroxyl groups;
with the proviso that the compound is other than compound number 38, 138, 212, 243, 378, 415, 441, 480, 577, 579, 580, 587-589, 593, 598, 600, 629, 636, 678, 684, 747, 760, 802, 861, 871, 873, 879, 883, 897-899, 904-905, 907, 909, 915, 917-919, 922-923, 925, 929-930, 938-939, 961. - In one embodiment, the compound of formula (IA) is selected from any of compounds: 1, 4-17, 19-25, 36-37, 39-40, 42, 44-45, 52, 61, 71-76, 80-83, 86-91, 93-97, 102-107, 110-112, 114, 117-122, 139-143, 149-151, 153, 158-160, 163-170, 174-177, 185-197, 200, 202-203,208-209, 211, 213-221, 223-224, 226, 228-229, 232, 234, 237-240, 256, 261-264, 267-268, 270, 272, 275-283, 296, 304, 313, 319, 321-323, 326-328, 332, 334-335, 342-345, 350, 356, 361-365, 367-369, 372, 377, 379, 383, 393, 398, 403, 406, 412-413, 416-423, 431-432, 434, 436, 438-440, 442-447, 460, 463, 465-466, 468-476, 478, 481, 487-488, 492-494, 499, 501, 506, 508-510, 512-515, 517-518, 521-522, 525, 527-529, 531-532, 534, 551-552, 554-555, 558, 562-563, 569, 573, 576, 578, 581-582, 584, 586, 599, 604-605, 610-614, 617, 619, 623-625, 628, 630, 633-635, 639, 643-644, 650-652, 654, 656, 664-667, 670, 672, 676-677, 679, 683, 695, 697-698, 704, 707-708, 710, 714, 717, 733, 736, 741-743, 750, 761-766, 768, 773, 782, 787, 791, 794, 807, 809-812, 815-816, 820, 841-843, 846, 849-856, 859-860, 862-864, 931, 947-948, 967, 970, 982, 984, 989, 991-992, 1000 and 1002 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a further embodiment, the compound of formula (IA) is selected from any of compounds: 5-6, 9-11, 16-17, 19-20, 23-25, 37, 39-40, 42, 44-45, 52, 71, 73, 76, 80-83, 86-87, 89, 91, 93-94, 96-97, 102, 104-106, 111-112, 114, 117-122, 139-143, 149-151, 153, 159, 164, 166, 168, 174-177, 185-187, 190, 192, 195-197, 202-203, 208-209, 211, 214-221, 223-224, 226, 228-229, 232, 234, 237-238, 240, 261-264, 267, 270, 275-283, 313, 319, 321-322, 327-328, 332, 334-335, 342-345, 350, 361-365, 367, 369, 372, 377, 379, 383, 393, 398, 403, 406, 412-413, 416-419, 421, 423, 431-432, 440, 442-445, 447, 463, 465-466, 469-472, 474-476, 478, 481, 488, 494, 499, 501, 506, 508-510, 512-513, 515, 518, 521-522, 525, 528, 532, 552, 554-555, 558, 562, 569, 576, 578, 582, 584 and 586 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a yet further embodiment, the compound of formula (IA) is selected from any of compounds:
- 10, 25, 45, 223, 240, 281-282, 321, 465, 506, 512, 611-614, 623-624, 633, 654, 656, 670, 676-677, 697, 717, 736, 766, 851 and 856 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a still yet further embodiment, the compound of formula (IA) is selected from any of compounds: 10, 45, 240, 654, 656, 766 and 856 as described herein or a pharmaceutically acceptable salt or solvate thereof, such as compounds 10, 654 and 856.
- In one embodiment, the compound of formula (IA) is selected from any of compounds: 10, 25, 42, 45, 223, 240, 281-282, 321, 439, 465, 506, 512, 611-614, 619, 623-624, 633, 639, 654, 656, 670, 672, 676-677, 683, 697, 717, 736, 761, 765-766, 768, 809-810, 820, 842, 851, 856, 859-860, 863, 931, 947-948, 967, 970, 982, 984, 989, 991-992, 1000 and 1002 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 5%.
- In one embodiment, the compound of formula (IA) is selected from any of compounds:
- 10, 42, 45, 240, 654, 656, 766, 856, 859, 863, 931, 947-948 and 967 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 50%.
- In one embodiment, the compound of formula (IA) is selected from any of compounds: 10, 654, 856, 859, 931 and 947 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 90%.
- According to a second aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (IB) or a pharmaceutically acceptable salt or solvate thereof:
- wherein
“Het B” represents a 5 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
Z represents a bond, —C(R7b)(R8b)—, (CH2)2, —O—, —S—, —CH2—O—, —(CH2)2—O—, NR6b, —N(R6bb)—C(R7b)(R8b)—, —N(R6b)—(CH2)2—, —N(R6b)—(CH2)3—, —CH2—N(R6b)—(CH2)2—, —N(R6b)—OO—, —CH2—NH—CO—(CH2)2—, —N(R6b)—CO—CH2—, ═N—, —C(H)(CN)—, —C(═N—NH—COC1-6alkyl)—, —CH═C(R6b)—CO—, ═CH—, —N═CH—, —N═C(Me)—, —C(R6b)═CH—, —NH—CO—C(═CH-heteroaryl)-, —C═C(Me)2—, —CH═CH—CO—N(R6b)—, —CH═C(R6b)—CO—NH—CH2—, —CH═C(R6b)—NH—CO—, —CH═C(R6b)—CO—O—CH2—, —CS—S—CH2—, —NH—CS—NH—, —NH—CS—NH—CH2—, —NH—CS—NH—(CH2)2—, —CH2—N(CSNH2)—CH2—, —S—C(R5b)(R6b)—, —S—(CH2)2—O—, SO2, —NH—SO2—, —CH2—NH—SO2—, CO, —CH2—CO—, —(CH2)2—CO—, —O—CH2—CO—, —(CH2)2—CO—, COO, —COO—C(R7b)CO—, —CH═C(R5b)—CONN—CH2—, CO—CH2—N(R6b)—CO—, —CO—CH2—C(R6b)—CH2—CO—, —CO—CH2—N(R6b)—CH2—, —CO—NH—N═C(R7b)—, —S—CH2—CO—, —S—CH2—CO—N(R6b)—, —S—CH2—CO—N(R6b)—CH2—, —SO2—N(R6b)—C(R7b)(R8b—CONH—, —SO2—N(R6b)—CH(—CH2-aryl)-CONH—CH2—, —CH(—S—C1-6 alkyl)-C(Me)(OH)—, —CH2—C(R6b)(OH)—, —C(OH)(CH(Me)(C3-8 cycloalkyl))-CH2—, —C(OH)(R6b)—CH2—, CH(Me)—NH—CO—CH2—, —CO—N(R6b)—CH2—, —C(H)(R6b)—CO—N(R5b)—CH2—, —CO—N(R6b)—CH2—CH2—, —CO—N(R6b)—CH2—CH2—CO—NH—CH2—, —CO—NH—C(—CONH2)═CH—, —CO—NH—CH(—CONH2)—CH2—, —CH2—C(H)(Me)—CH2—S—, —O—CH2—CO—NH—, —CH2—N(R6b)—CO—CH2—O—, —N(R6b)—CO—CH2—O—, —C(H)(—CH2-aryl)-, —C(H)(—CH2-heteroaryl)-, —C(NH-aryl)=N—N═CH—, —C(NH-aryl)=N—N═CH—, —NH—CO—CH2—N(R6b)—, —NH—N═C(-aryl)-, —NH—N═C(-aryl)-CO—, —NH—C(═N—CO—C1-6 alkyl)-NH—(CH2)2—, —C(—NH-aryl)=N—N═CH—, —NH—C(—NH-aryl)=N—CONH—, —C(═CH-aryl)-CONH—CH2—, —CH═C(R6b)—CONH—, —CH(—CH2-aryl)-NH—CO— or —CH(OH)—, wherein said aryl or heteroaryl groups of Z may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6alkoxy, NO2 or hydroxyl groups;
R5b represents hydrogen, C1-6 alkyl or cyano;
R6b represents hydrogen, C1-6 alkyl, C1-6 alkoxy, cyano, COOH, —COOC1-6alkyl, C3-8 cycloalkyl, —CH2—C3-8 cycloalkyl, aryl, heteroaryl, —C1-6 alkylene-aryl, —CO-aryl, —O—CO-heteroaryl, —CO—heteroaryl or —C(R7b)(R8b)-heteroaryl, wherein said aryl groups of R6b may be optionally substituted by one or more halogen or C1-6 alkoxy groups;
R7b and R8b independently represent hydrogen or C1-6 alkyl;
R1b represents aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein Rib may be substituted by one or more (e.g. 1, 2 or 3) R4b groups;
R4b represents halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C3-8 cycloalkyl, haloC1-6 alkyl, hydroxyl, C1-6 alkoxy, alkenyl, haloC1-6alkoxy, —COOH, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —CONH2, —CH2—CONH2, —NH—C1-6 alkyl, —NH—C2-6 alkenyl, —NH—CO—C1-6 alkyl, —CO—NH—C1-6 alkyl, —O—CH2—CO—NH—C1-6 alkyl, —CH2—CH2—CO—NH—C1-6 alkyl, —S—C1-6 alkyl, —SO—C1-6 alkyl, —SO2—C1-6alkyl, —SO2—NH—C1-6 alkyl, —S—CH2—CO—C2-6alkenyl, —SO2—OH, amino, cyano, NO2, ═O, —CO—NH—(CH2)2)—OMe, —NH—C3-8 cycloalkyl, —CH2—CO—NH—C3-8 cycloalkyl, —CO-heterocyclyl, —CO-heteroaryl, —COO—(CH2)2-heterocyclyl, —OCH2-aryl, —OCH2-heteroaryl, —CH2—O—CO-aryl, —O-aryl, —NH—CO-aryl, —NH—CO-heteroaryl, —NH—CO—CH2-aryl, —NH-aryl, aryl or heteroaryl groups, wherein said aryl, heterocyclyl or heteroaryl groups of R4b may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, ═S or hydroxyl groups and wherein said C1-6 alkyl or C2-6 alkenyl groups of R4b may be optionally substituted by one or more hydroxyl, amino, cyano, C1-6 alkoxy, CONH2 or -COO-C1-6 alkyl groups;
m represents an integer from 0 to 3;
R2b represents halogen, haloC1-6 alkyl, C1-6 alkyl, hydroxyl, C1-6 alkoxy, —S—C1-6 alkyl, —CH2—S—C1-6 alkyl, —S—C2-6 alkynyl, amino, cyano, NO2, ═O, ═S, —SO2—C1-6 alkyl, —CONH2, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —NH—C1-6 alkyl, —NH—CO—C1-6 alkyl, —NH—CO—CH═CH—CH2—N(Me)2, C1-6 alkyl, —CO—NH—C1-6 alkyl, —CO—NH—CH(Me)—COOH, —S—CH2—CO—N(Et)2, —NH—(CH2)2—OH, —NH—(CH2)3—OH, —NH—CH(Et)—CH2—OH, —CO—NH—(CH2)3—OH, —CH(CH2OH)2 or —S—CH2—CO—NH—CO—NH—C1-6 alkyl, wherein said C1-6 alkyl groups of R2b may be optionally substituted by one or more hydroxyl groups;
with the proviso that the compound is other than compound number 54, 373, 458, 496, 585, 590, 594, 596-597, 601-602, 649, 703, 778, 877, 891, 910, 912, 926 and 962-963. - In one embodiment, the compound of formula (IB) is selected from any of compounds 2-3, 26-28, 30-33, 35, 47-48, 51, 57-60, 63-64, 78, 84, 113, 123, 127-129, 145, 155-157, 171-173, 204, 206-207, 210, 225, 227, 233, 235-236, 241-242, 244, 249, 269, 285, 288, 303, 307-312, 314-316, 320, 324-325, 333, 336, 351, 357-360, 374-375, 384-391, 396, 399-402, 404-405, 407-411, 414, 424-425, 427-428, 437, 448, 456-457, 482, 484-485, 489-491, 495, 497-498, 505, 507, 516, 519, 524, 526, 553, 559-560, 568, 570, 575, 609, 615-616, 618, 626-627, 638, 653, 669, 692-694, 705, 709, 712, 716, 719, 725, 734, 738, 740, 746, 749, 753-754, 756, 758-759, 767, 770, 777, 784-785, 790, 792, 796, 800-801, 804- 805, 808, 819, 821, 827-828, 831, 833, 838, 844, 847, 857-858, 869, 872, 875, 933, 952, 955, 969, 987, 990 and 999 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a further embodiment, the compound of formula (IB) is selected from any of compounds: 2-3, 26-28, 30, 32-33, 47-48, 51, 59-60, 84, 113, 123, 127, 129, 145, 155, 157, 172-173, 204, 206-207, 210, 225, 233, 235-236, 241, 244, 269, 285, 288, 307-311, 315-316, 320, 324-325, 333, 336, 351, 357-360, 374-375, 385-386, 388-391, 396, 399-402, 404-405, 407-410, 414, 424, 427-428, 437, 457, 482, 490, 495, 497-498, 505, 516, 519, 553, 559- 560 and 568 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a yet further embodiment, the compound of formula (IB) is selected from any of compounds:
- 30, 314, 324-325, 391, 405, 626, 705, 753-754, 759, 770, 784, 808, 833 and 847 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a still yet further embodiment, the compound of formula (IB) is selected from any of compounds:
- 324-325, 405, 754 and 847 as described herein or a pharmaceutically acceptable salt or solvate thereof, such as compound 324.
- According to a third aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (IC) or a pharmaceutically acceptable salt or solvate thereof:
- wherein
“Het C” represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
Xc and Yc independently represent a bond, —C(R7c)(R8c)—, (CH2)2, —O—, —S—, —CH2—O—, —(CH2)2—O—, NR6c, —N(R6c)—C(R7c)(R8c)—, —N(R6c)—(CH2)2—, —N(R6c)—(CH2)3—, —CH2—N(R6c)—(CH2)2—, —N(R6c)—CO—, —CH2—NH—CO—(CH2)2—, —N(R6c)—CO—CH2—, —CO—N(R6c)—CH2—, ═N—, —C(H)(CN)—, —C(═N—NH—COC1-6 alkyl)-, —CH═C(R6c)—CO—, ═CH—, —N═CH—, —N═C(Me)—, —C(R6c)═CH—, —NH—CO—C(═CH-heteroaryl)-, —C═C(Me)2—, —CH═CH—CO—N(R6c)—, —CH═C(R6c)—NH—CO—, —CH═C(R6c)—CO—O—CH2—, —CS—S—CH2—, —NH—CS—NH—, —NH—CS—NH—CH2—, —NH—CS—NH—(CH2)2—, —CH2—N(CSNH2)—CH2—, —S—CH2—, —S—(CH2)2—O—, SO2, —NH—SO2—, —CH2—NH—SO2—, CO, —CH2—CO—, —(CH2)2—CO—, —O—CH2—CO—, —(CH2)2—CO—, COO, —COO—C(R6c)(1R7c)CO—, —CH═C(R5c)—CONH—CH2—, —CO—CH2—N(R6c)—CO—, —CO—CH2—C(R6c)—CH2—CO—, —CO—CH2—N(R6c)—CH2—, —CO—NH—N═C(R7c)—, —S—CH2—CO—, —S—CH2—CO—N(R6c)—, —S—CH2—CO—N(R6c—CH2—, —SO2—N(R6c)—C(R7c)(R8c)—CONH—, —SO2—N(R6c)—CH(—CH2-aryl)-CONH—CH2—, —CH(—S—C1-6 alkyl)-C(Me)(OH)—, —CH2—C(R6c)(OH)—, —C(OH)(CH(Me)(C3-8 cycloalkyl))-CH2—, —C(OH)(R6c)—CH2—, —CH(Me)—NH—CO—CH2—, —CO—N(R6c)—CH2—, —CO—N(R6c)—CH2—CH2—, —CO—N(R6c)—CH2—CH2—CO—NH—CH2—, —CO—NH—C(—CONH2)═CH—, —CO—NH—CH(—CONH2)—CH2—, —CH2—C(H)(Me)—CH2—S—, —O—CH2—CO—NH—, —CH2—N(R6c)—CO—CH2—O—, —N(R6c)—CO—CH2—O—, —C(H)(—CH2-aryl)-, —C(H)(—CH2-heteroaryl)-, —C(NH—aryl)=N—N═CH—, —C(NH-aryl)=N—N═CH—, —NH—N═C(-aryl)-, —NH—N═C(-aryl)-CO—, —NH—C(═N—CO—C1-6 alkyl)-NH—(CH2)2—, —C(—NH-aryl)=N—N═CH—, —NH—C(—NH-aryl)=N—CONH—, —C(═CH-aryl)-CONH—CH2—, —CH═C(R6c)—CONH—, —CH(—CH2-aryl)-NH—CO— or —CH(OH)—, wherein said aryl or heteroaryl groups of Xc and Yc may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, NO2 or hydroxyl groups;
R5c represents hydrogen, C1-6 alkyl or cyano;
R6c represents hydrogen, C1-6 alkyl, C1-6 alkoxy, cyano, C3-8 cycloalkyl, —CH2—C3-8 cycloalkyl, aryl, heteroaryl, —C1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R7c)(R8c)-heteroaryl, wherein said aryl groups of R6c may be optionally substituted by one or more halogen or C1-6 alkoxy groups;
R7c and R8c independently represent hydrogen or C1-6 alkyl;
R1c and R2c independently represent aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R1c and R2c may be substituted by one or more (e.g. 1, 2 or 3) R4c groups;
R4c represents halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C3-8 cycloalkyl, haloC1-6 alkyl, hydroxyl, C1-6 alkoxy, —O—C1-6 alkenyl, haloC1-6 alkoxy, —COOH, —COO—C1-6 alkyl, —COO—C1-6 alkyl, —CONH2, —CH2—CONH2, —NH—C1-6 alkyl, —NH—C2-6 alkenyl, —NH—CO—C1-6 alkyl, —CO—NH—C1-6 alkyl, —O—CH2—CO—NH—C1-6 alkyl, —CH2—CH2—CO—NH—C1-6 alkyl, —S—C1-6 alkyl, —SO—C1-6 alkyl, —SO2—C1-6 alkyl, —SO2—NH—C1-6 alkyl, —S—CH2—CO—C2-6alkenyl, —SO2—OH, amino, cyano, NO2, ═O, —CO—NH—(CH2)2)—OMe, —NH—C3-8 cycloalkyl, —CO-heterocyclyl, —CO-heteroaryl, —COO—(CH2)2-heterocyclyl, —OCH2-aryl, —OCH2-heteroaryl, —CH2—O—CO-aryl, —O-aryl, —NH—CO-heteroaryl, —NH—CO—CH2-aryl, aryl or heteroaryl groups, wherein said aryl, heterocyclyl or heteroaryl groups of R4c may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, ═S or hydroxyl groups and wherein said C1-6 alkyl or C2-6 alkenyl groups of R4c may be optionally substituted by one or more hydroxyl, amino, cyano, C1-6 alkoxy, CONH2 or —COO—C1-6 alkyl groups;
p represents an integer from 0 to 3;
R3c represents halogen, haloC1-6 alkyl, C1-6 alkyl, hydroxyl, C1-6 alkoxy, —S—C1-6 alkyl, —CH2—S—C1-6 alkyl, —S—C2-6 alkynyl, amino, cyano, NO2, ═O, ═S, —SO2—C1-6 alkyl, —CONH2, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —NH—C1-6 alkyl, —NH—CO—C1-6 alkyl, —NH—CO—CH═CH—CH2—N(Me)2, C1-6 alkyl, —CO—NH—C1-6 alkyl, —CO—NH—CH(Me)—COOH, —S—CH2—CO—N(Et)2, —NH—(CH2)2—OH, —NH—(CH2)3—OH, —NH—CH(Et)—CH2—OH, —CO—NH—(CH2)3—OH, —CH(CH2OH)2 or —S—CH2—CO—NH—CO—NH—C1-6 alkyl, aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein said aryl, heterocyclyl or heteroaryl groups of R3c may be optionally substituted by one or more (e.g. 1, 2 or 3) R4c groups and wherein said C1-6 alkyl groups of R3c may be optionally substituted by one or more hydroxyl groups; with the proviso that the compound is other than compound number 161, 648, 658, 680, 726, 824, 867, 880, 892, 896, 901, 903, 906, 928 and 944. - In one embodiment, Het C represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to one further ring to form a bicyclic ring system. In a further embodiment, Het C represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to a phenyl ring to form a bicyclic ring system. In a yet further embodiment, Het C represents a 6 membered heterocyclic ring system containing 1 or 2 nitrogen atoms, wherein said ring system is optionally fused to a phenyl ring to form a bicyclic ring system. In a yet further embodiment, Het C represents pyridinyl, pyrimidinyl or quinazolinyl. In a yet further embodiment, Het C represents quinazolinyl.
- In one embodiment, Xc and Yc independently represent a bond or NR6c. In a further embodiment, Xc and Yc independently represent a bond or NH. In a yet further embodiment, one of Xc and Yc represents a bond and the other represents a bond or NH. In a yet further embodiment, one of Xc and Yc represents a bond and the other represents NH.
- In one embodiment, R1c and R2c independently represent aryl, bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R1c and R2c may be substituted by one or more (e.g. 1, 2 or 3) R4c groups. In a further embodiment, R1c and R2c independently represent aryl (e.g. phenyl), bicyclic heterocyclyl (e.g. benzodioxinyl), monocyclic heteroaryl (e.g. pyridinyl, pyrazolyl or thiophenyl) or bicyclic heteroaryl ring system (e.g. benzoxazolyl), wherein R1c and R2c may be substituted by one or more (e.g. 1, 2 or 3) R4c groups. In a yet further embodiment, R1c and R2c independently represent aryl (e.g. phenyl), bicyclic heterocyclyl (e.g. benzodioxinyl), monocyclic heteroaryl (e.g. pyridinyl, pyrazolyl or thiophenyl) or bicyclic heteroaryl ring system (e.g. benzoxazolyl), wherein R1c and R2c may be substituted by one or more (e.g. 1) R4c groups selected from hydroxyl, C1 -6 alkoxy (e.g. methoxy) or —CONH2.
- In a yet further embodiment, R1c and R2c independently represent aryl (e.g. phenyl) or monocyclic heteroaryl (e.g. pyridinyl, pyrazolyl or thiophenyl) wherein R1c and R2c may be substituted by one or more (e.g. 1) R4c groups selected from hydroxyl, C1-6 alkoxy (e.g. methoxy) or —CONH2.
- In a yet further embodiment, R1c and R2c independently represent unsubstituted aryl (e.g. phenyl) or unsubstituted monocyclic heteroaryl (e.g. pyridinyl or pyrazolyl).
- In a yet further embodiment, one of R1c and R2c represents unsubstituted aryl (e.g. phenyl) and the other represents unsubstituted monocyclic heteroaryl (e.g. pyridinyl or pyrazolyl).
- In one embodiment, p represents an integer from 0 to 2. In one embodiment, p represents 0. In an alternative embodiment, p represents 1. In an alternative embodiment, p represents 2.
- In one embodiment, R3c represents ═O, cyano or a monocyclic heteroaryl ring system (e.g. pyridinyl).
- In one embodiment, when p represents 1, R3c represents a monocyclic heteroaryl ring system (e.g. pyridinyl).
- In one embodiment, when p represents 2, R3c represents ═O and cyano.
- In one embodiment, the compound of formula (IC) is selected from any of compounds:
- 43, 46, 49, 147, 152, 154, 178-181, 183-184, 294-295, 305, 329, 339-341, 366, 370-371, 376, 435, 455, 459, 462, 486, 520, 539-543, 546-549, 556-557, 567, 631-632, 640-642, 645, 657, 661, 668, 671, 674, 681, 700-702, 727, 735, 755, 817-818, 823, 826, 845 or 865-866, 868, 870, 888-890, 894, 946, 949-951, 953, 957, 973, 977, 981, 983, 985-986, 993 and 995 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a further embodiment, the compound of formula (IC) is selected from any of compounds: 46, 147, 294-295, 329, 341, 435, 486, 520, 539, 542-543, 547-549, 556 and 567 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a yet further embodiment, the compound of formula (IC) is selected from any of compounds:
- 567, 631, 640, 661 and 700 as described herein or a pharmaceutically acceptable salt or solvate thereof, such as compound 700.
- In one embodiment, the compound of formula (IC) is selected from any of compounds: 567, 631, 640, 661, 668, 700, 727, 823, 868, 870, 888-890, 894, 946, 949-951, 953, 957, 973, 977, 981, 983, 985-986, 993 and 995 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 5%.
- In one embodiment, the compound of formula (IC) is selected from any of compounds:
- 2-Phenyl-N-(pyridin-4-yl)quinazolin-4-amine (Compound 700);
- N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-phenylquinazolin-4-amine (Compound 868);
- 4-{[2-(Thiophen-3-yl)quinazolin-4-yl]amino}benzamide (Compound 870);
- 2-Phenyl-N-(1H-pyrazol-4-yl)quinazolin-4-amine (Compound 894);
- 2[2-Methyl-4-(pyridin-4-yl)pyrimidin-5-yl]-1,3-benzoxazole (Compound 949);
- 2-[2-(Pyridin-2-yl)-4-(pyridin-4-yl)pyrimidin-5-yl]-1,3-benzoxazole (Compound 950);
- 5-(1,3-Benzoxazol-2-yl)-2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile (Compound 951);
- 4-[(2-Phenylquinazolin-4-yl)amino]phenol (Compound 957);
- N-(4-Methoxyphenyl)-2-(thiophen-2-yl)quinazolin-4-amine (Compound 973);
- N-(4-Methoxyphenyl)-2-(pyridin-2-yl)quinazolin-4-amine (Compound 977);
- 6-Phenyl-2-(pyridin-2-yl)-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 986); and
- 4-[(2-Phenylquinazolin-4-yl)amino]benzamide (Compound 993);
- or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 25%.
- In a further embodiment, the compound of formula (IC) is selected from any of compounds:
- 2-Phenyl-N-(pyridin-4-yl)quinazolin-4-amine (Compound 700);
- 2-Phenyl-N-(1H-pyrazol-4-yl)quinazolin-4-amine (Compound 894);
- 2-[2-Methyl-4-(pyridin-4-yl)pyrimidin-5-yl]-1,3-benzoxazole (Compound 949); and
- 6-Phenyl-2-(pyridin-2-yl)-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 986);
- or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 50%.
- In a yet further embodiment, the compound of formula (IC) is selected from any of compounds:
- 2-Phenyl-N-(pyridin-4-yl)quinazolin-4-amine (Compound 700); and
- 2-Phenyl-N-(1H-pyrazol-4-yl)quinazolin-4-amine (Compound 894);
- or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 80%.
- According to a fourth aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (ID) or a pharmaceutically acceptable salt or solvate thereof:
- wherein
“Het D” represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
Zd represents a bond, —C(R7d)(R8d)—, —(CH2)—C(R7d)(R8d)—, —O—, —S—, —CH2—O—, —(CH2)2—O—, NR6d, —N(R6d)—C(R7d)(R8d)—, —N(R6d)—(CH2)2—, —N(R6d)—(CH2)3—, —CH2—N(R6d)—(CH2)2—, —N(R6)—CO—, —CH2—NH—CO—(CH2)2—, —N(R6d)—CO—CH2—, —CO—N(R6d)—CH2—, ═N—, —C(H)(CN)—, —C(═N—NH—COC1-6 alkyl)-, —CH═C(R6d)—CO—, ═CH—, —N═CH—, —N═C(Me)—, —C(R6d)═CH—, —NH—CO—C(═CH-heteroaryl)-, —C═C(Me)2—, —CH═CH—CO—N(R6d)—, —CH═C(R6d)—NH—CO—, —CO—O—CH2—, —CH═C(R6d)—CO—O—CH2—, —CS—S—CH2—, —NH—CO—NH—, —NH—CS—NH—, —NH—CS—NH—CH2—, —NH—CS—NH—(CH2)2—, —CH2—N(CSNH2)—CH2—, —S—CH2—, —S—(CH2)2—O—, SO2, —NH—SO2—, —CH2—NH—SO2—, CO, —CH2—CO—, —(CH2)2—CO—, —O—CH2—CO—, —(CH2)2—CO—, COO, —COO—C(R7d)CO—, —CH═C(R5d)—CONH—CH2—, —CO—CH2—N(R6d)—CO—, —CO—CH2—C(R6d)—CH2—CO—, —CO—CH2—N(R6d)—CH2—, —CO—NH—N═C(R7d)—, —S—CH2—CO—, —S—CH2—CO—N(R6d)—, —S—CH2—CO—N(R6d)—CH2—, —SO2—N(R6d)—C(R7d)(R8d)—CONH—, —SO2—N(R6d)—CH(—CH2-aryl)-CONH—CH2—, —CH(—S—C1-6 alkyl)-C(Me)(OH)—, —CH2—C(R6d)(OH)—, —C(OH)(CH(Me)(C3-8 cycloalkyl))- CH2—, —C(OH)(R6d)—CH2—, —CH(Me)—NH—CO—CH2—, —CO—N(R6d)—CH2—, —CO—N(R6d)—CH2—CH2—, —CO—N(R6d)—CH2—CH2—CO—NH—CH2—, —CO—NH—C(—CONH2)═CH—, —CO—NH—CH(—CONH2)—CH2—, —CH2—C(H)(Me)—CH2—S—, —O—CH2—CO—NH—, —CH2—N(R6d)—CO—CH2—O—, —N(R6d)—CO—CH2—O—, —C(H)(—CH2-aryl)-, —C(H)(—CH2-heteroaryl)-, —C(NH-aryl)=N—N═CH—, —C(NH-aryl)=N—N═CH—, —NH—N═C(-aryl)-, —NH—N═C(-aryl)-CO—, —NH—C(═N—CO—C1-6 alkyl)-NH—(CH2)2—, —C(—NH-aryl)=N—N═CH—, —NH—C(-NH-aryl)=N—CONH—, —C(═CH-aryl)-CONH—CH2—, —CH═C(R6d)—CONH—, —CH(—CH2-aryl)-NH—CO— or —CH(OH)—, wherein said aryl or heteroaryl groups of Zd may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, NO2 or hydroxyl groups;
R5d represents hydrogen, C1-6 alkyl or cyano;
R6d represents hydrogen, C1-6 alkyl, C1-6 alkoxy, cyano, C3-8 cycloalkyl, —CH2—C3-8 cycloalkyl, aryl, heteroaryl, —C1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R7d)(R8d)-heteroaryl, wherein said aryl groups of R6d may be optionally substituted by one or more halogen or C1-6 alkoxy groups;
R7d and R8d independently represent hydrogen or C1-6 alkyl;
R1d represents aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R1d may be substituted by one or more (e.g. 1, 2 or 3) R4d groups;
R4d represents halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C3-8 cycloalkyl, haloC1-6 alkyl, hydroxyl, C1-6 alkoxy alkoxy, —COOH, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —CONH2, —CH2—CONH2, —NH—C1-6 alkyl, —NH—C2-6 alkenyl, —NH—CO—C1-6 alkyl, —CO—NH—C1-6 alkyl, —O—CH2—CO—NH—C1-6 alkyl, —CH2—CH2—CO—NH—C1-6 alkyl, —S—C1-6 alkyl, —SO—C1-6 alkyl, —SO2—C1-6 alkyl, —SO2—NH—C1-6 alkyl, —S—CH2—CO—C2-6alkenyl, —SO2—OH, amino, cyano, NO2, ═O, —CO—NH—(CH2)2)—OMe, —NH—C3-8 cycloalkyl, —CO-heterocyclyl, —CO-heteroaryl, —COO—(CH2)2-heterocyclyl, —OCH2-aryl, —OCH2-heteroaryl, —CH2—O—CO-aryl, —O-aryl, —NH—CO-aryl, —NH—CO-heteroaryl, —NH—CO—CH2-aryl, aryl or heteroaryl groups, wherein said aryl, heterocyclyl or heteroaryl groups of R4d may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, ═S or hydroxyl groups and wherein said C1-6 alkyl or C2-6 alkenyl groups of R4d may be optionally substituted by one or more hydroxyl, amino, cyano, C1-6 alkoxy, CONH2 or —COO—C1-6 alkyl groups;
q represents an integer from 0 to 3;
R2d represents halogen, haloC1-6 alkyl, C1-6 alkyl, hydroxyl, C1-6 alkoxy, —S—C1-6 alkyl, —CH2—S—C1-6 alkyl, —S—C2-6 alkynyl, amino, cyano, NO2, ═O, ═S, ═NH, —SO2—C1-6 alkyl, —CONH2, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —NH—C1-6 alkyl, —NH—CO—C1-6 alkyl, —NH—CO—CH═CH—CH2—N(Me)2, C1-6 alkyl, —CO—NH—C1-6 alkyl, —CO—NH—CH(Me)—COOH, —S—CH2—CO—N(Et)2, —NH—(CH2)2—OH, —NH—(CH2)3—OH, —NH—CH(Et)—CH2—OH, —CO—NH—(CH2)3—OH, —CH(CH2OH)2 or —S—CH2—CO—NH—CO—NH—C1-6 alkyl, wherein said C1-6 alkyl groups of R2d may be optionally substituted by one or more hydroxyl groups;
with the proviso that the compound is other than compound number 273, 286, 467, 533, 544, 571, 591, 662, 783, 795, 806, 884, 887, 895, 902, 908, 921, 932, 934, 942, 959-960 and 1001. - In one embodiment, the compound of formula (ID) is selected from any of compounds: 29, 34, 41, 65-70, 92, 109, 116, 126, 130-137, 162, 182, 231, 246, 252-255, 258, 274, 290-293, 297-298, 317-318, 330-331, 347-349, 352, 450-454, 483, 536-538, 545, 550, 564-565, 572, 620, 637, 655, 663, 675, 682, 686, 691, 696, 706, 711, 724, 728-729, 737, 744-745, 748, 752, 774-776, 781, 797-799, 832, 834, 954, 958, 964-965, 971, 974-976, 978-980, 994 and 997-998 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a further embodiment, the compound of formula (ID) is selected from any of compounds: 34, 41, 65-66, 68-69, 109, 126, 130, 132-137, 162, 182, 231, 246, 252-255, 258, 274, 290, 293, 297-298, 317-318, 348-349, 352, 450-453, 536, 545, 550, 564-565 and 572 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a yet further embodiment, the compound of formula (ID) is selected from any of compounds:
- 663, 682, 696, 737, 748, 832 and 834 as described herein or a pharmaceutically acceptable salt or solvate thereof, such as compound 682.
- In one embodiment, the compound of formula (ID) is selected from any of compounds: 663, 675, 682, 696, 706, 737, 748, 797, 832, 834, 954, 958, 964-965, 971, 974-976, 978980, 994 and 997-998 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 5%.
- In one embodiment, the compound of formula (ID) is selected from any of compounds: 682, 954, 964, 978-979 and 997 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 50%.
- According to a fifth aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (1E) or a pharmaceutically acceptable salt or solvate thereof:
- wherein
“Het E” represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S;
Ze represents a bond, —C(R7e)(R8e)—, (CH2)2, —O—, —S—, —CH2—O—, —(CH2)2—O—, NR6e, —N(R6e)—C(R7e)(R8e)—, —N(R6e)—(CH2)2—, —N(R6e)—(CH2)3—, —CH2—N(R6e)—(CH2)2—, —N(R6e)—CO—, —CH2—NH—CO—(CH2)2—, —N(R6e)—CO—CH2—, —CO—N(R6e)—CH2—, ═N—, —C(H)(CN)—, —C(═N—NH—COC1-6 alkyl)-, —C(R6e)═N—NH—CO—, —CH═C(R6e)—CO—, ═CH—, —N═CH—, —N═C(Me)—, —C(R6e)═CH—, —NH—CO—C(═CH-heteroaryl)-, —C═C(Me)2—, —CH═CH—CO—N(R6e)—, —CH═C(R6e)—NH—CO—, —CH═C(R6e)—CO—O—CH2—, —CS—S—CH2—, —NH—CS—NH—, —N(R6e)—CO—N(R7e)—, —NH—CS—N(R6e)—CH(R7e)—, —CO—NH—CS—N(R6e)—, —NH—CS—NH—(CH2)2—, —CH2—N(CSNH2)—CH2—, —S—CH2—, —S—(CH2)2—O—, SO2, —NH—SO2—, —CH2—N(R6e)—SO2—, CO, —CH2—CO—, —(CH2)2—CO—, —O—CH2—CO—, —(CH2)2—CO—, COO, —COO—C(R7e)CO—, —CH═C(R5e)—CONH—CH2—, —CO—CH2—N(R6e)—CO—, —CO—CH2—C(R6e)—CH2—CO—, —C(R6e)—CO—CH2—, —CO—CH2—N(R6e)—CH2—, —CO—NH—N═C(R7e)—, —S—CH2—CO—, —S—CH2—CO—N(R6e)—, —S—CH2—CO—N(R6e)—CH2—, —SO2—N(R6e)—C(R7e)(R8e)—CONH—, —SO2—N(R6e)—CH(—CH2-aryl)-CONH—CH2—, —CH(—S—C1-6 alkyl)—C(Me)(OH)—, —CH2—C(R6e)(OH)—, —C(OH)(CH(Me)(C3-8 cycloalkyl))-CH2—, —C(OH)(R6e)—CH2—, —CH(Me)—NH—CO—CH2—, —CO—N(R6e)—CH2—, —CO—N(R6e)—CH2—CH2—, —CO—N(R6e)—CH2—CH2—O—CO—, —CO—N(R6e)—CH2—CH2—CO—NH—CH2—, —CO—NH—C(—CONH2)═CH—, —CO—NH—CH(—CONH2)—CH2—, —CH2—C(H)(Me)—CH2—S—, —O—CH2—CO—NH—, —CH2—N(R6e)—CO—CH2—O—, —N(R6e)—CO—CH2—O—, —C(H)(—CH2-aryl)-, —C(H)(—CH2-heteroaryl)-, —C(NH-aryl)=N—N═CH—, —C(NH-aryl)=N—N═CH—, —NH—N═C(-aryl)-, —NH—C(R6e)═N—SO2—, —NH—N═C(-aryl)-CO—, —NH—C(═N—CO)(R6e)—, —NH—C(═N—CO—C1-6 alkyl)-NH—(CH2)2—, —C(—NH-aryl)=N—N═CH—, —NH—C(—NH-aryl)=N—CONH—, —C(═CH-aryl)-CONH—CH2—, —CH═C(R6e)—CONH—, —CH(—CH2-aryl)-NH—CO— or —CH(OH)—, wherein said aryl or heteroaryl groups of Ze may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6alkoxy, NO2 or hydroxyl groups;
R5e represents hydrogen, C1-6 alkyl or cyano;
R6e represents hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, cyano, C3-8 cycloalkyl, —CH2-C3-8 cycloalkyl, aryl, heteroaryl, —C1-6 alkylene-aryl, —C1-6 alkylene-heteroaryl, —NH—CO-aryl, —CO-aryl, —CO-heteroaryl or —C(R7e)(R8e)-heteroaryl, wherein said aryl groups of R6e may be optionally substituted by one or more halogen or C1-6 alkoxy groups;
R7e and R8e independently represent hydrogen or C1-6 alkyl;
R1e represents aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R1d may be substituted by one or more (e.g. 1, 2 or 3) R4e groups;
R4e represents halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C3-8 cycloalkyl, haloC1-6 alkyl, hydroxyl, C1-6 alkoxy, alkenyl, haloC1-6 alkoxy, —COOH, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —CONH2, —SO2NH2, —CH2—CONH2, —NH—C1-6 alkyl, —NH—C2-6 alkenyl, —NH—CO—C1-6 alkyl, —CO—NH—C1-6 alkyl, —NH—NH2, —O—CH2—CO—NH—C1-6 alkyl, —CH2—CH2—CO—NH—C1-6 alkyl, —S—C1-6 alkyl, —SO—C1-6 alkyl, —SO2—C1-6 alkyl, —SO2—NH—C1-6 alkyl, —S—CH2—CO—C2-6 alkenyl, —SO2—OH, amino, cyano, NO2, ═O, —CO—NH—(CH2)2)—OMe, —NH—C3-8 cycloalkyl, —CO-heterocyclyl, —CO-heteroaryl, —COO—(CH2)2-heterocyclyl, —OCH2-aryl, —OCH2-heteroaryl, —CH2—O—CO-aryl, —O-aryl, —CO—NH-aryl, —NH—SO2-aryl, —NH—CO-heteroaryl, —NH—C1-4 alkylene-heteroaryl, —NH—CO—CH2-aryl, aryl or heteroaryl groups, wherein said C1-6 alkynyl, aryl, heterocyclyl or heteroaryl groups of R4e may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, ═S or hydroxyl groups and wherein said C1-6 alkyl or C2-6 alkenyl groups of R4e may be optionally substituted by one or more hydroxyl, amino, cyano, C1-6 alkoxy, CONH2 or —COOC1-6 alkyl groups;
r represents an integer from 0 to 3;
R2e represents halogen, haloC1-6 alkyl, C1-6 alkyl, C1-6 alkynyl, hydroxyl, C1-6 alkoxy, —S—C1-6 alkyl, —CH2—S—C1-6alkyl, —S—C2-6 alkynyl, amino, cyano, NO2, ═O, ═S, —SO2—C1-6 alkyl, —CONH2, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —NH—C1-6 alkyl, —NH—CO—C1-6 alkyl, —NH—CO—CH═CH—CH2—N(Me)2, C1-6 alkyl, —CO—NH—C1-6 alkyl, —CO—NH—CH(Me)—COOH, —S—CH2—CO—N(Et)2, —NH—(CH2)2—OH, —NH—(CH2)3—OH, —NH—CH(Et)—CH2—OH, —CO—NH—(CH2)3—OH, —CH(CH2OH)2 or —S—CH2—CO—NH—CO—NH—C1-6alkyl, wherein said C1-6 alkyl or C1-6 alkynyl, groups of R2e may be optionally substituted by one or more hydroxyl or alkylamino groups; with the proviso that the compound is other than compound number 250, 647, 685, 751, 769, 803, 874, 876, 893, 900, 911, 913-914, 916, 920, 927, 936-937, 940, 943 and 945. - In one embodiment, the compound of formula (IE) is selected from any of compounds:
- 18, 50, 55-56, 62, 77, 85, 108, 115, 144, 146, 148, 198-199, 201, 222, 230, 245, 247, 251, 265, 284, 287, 300, 306, 337-338, 346, 381-382, 392, 426, 429-430, 479, 561, 566, 583, 603, 606-608, 621-622, 646, 659-660, 687-688, 690, 699, 715, 718, 720-723, 730732, 739, 771-772, 780, 793, 813-814, 822, 829-830, 835-837, 840, 848, 885-886, 941, 966 and 988 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a further embodiment, the compound of formula (IE) is selected from any of compounds: 18, 62, 115, 146, 148, 222, 230, 251, 265, 300, 306, 338, 346, 381, 392, 426, 561 and 583 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a yet further embodiment, the compound of formula (IE) is selected from any of compounds:
- 583, 660, 822 and 830 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In one embodiment, the compound of formula (IE) is selected from any of compounds: 583, 646, 660, 723, 730, 780, 822, 830, 885-886, 941, 966 and 988 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 5%.
- According to a sixth aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (IF) or a pharmaceutically acceptable salt or solvate thereof:
- wherein
“Het F” represents a heterocyclic ring system containing 1 to 3 heteroatoms selected from 0, N or S, wherein said ring system is fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
R1f represents halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C3-8 cycloalkyl, haloC1-6 alkyl hydroxyl, C1-6 alkoxy, —O—C1-6 alkenyl, haloC1-6 alkoxy, —COOH, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —CONH2, —CH2—CONH2, —NH—C1-6 alkyl, —NH—C2-6 alkenyl, —NH—CO—C1-6 alkyl, —CO—NH—C1-6 alkyl, —O—CH2—CO—NH—C1-6 alkyl, —CH2—CH2—CO—NH—C1-6 alkyl, —SO—C1-6 alkyl, —SO2—C1-6alkyl, —SO2—NH—C1-6 alkyl, —S—CH2—CO—C2-6 alkenyl, —SO2—OH, amino, cyano, NO2, ═O, —CO—NH—(CH2)2)—OMe, —NH—C3-8 cycloalkyl, wherein said C1-6 alkyl or C2-6 alkenyl groups of R1f may be optionally substituted by one or more hydroxyl, amino, cyano, C1-6 alkoxy, CONH2 or —COO—C1-6 alkyl groups;
s represents an integer from 1 to 3;
with the proviso that the compound is other than compound number 592 and 595. - In one embodiment, the compound of formula (IF) is selected from any of compounds: 53, 79, 124-125, 205, 289, 299, 301-302, 353-355, 397, 500 and 511 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a further embodiment, the compound of formula (IF) is selected from any of compounds: 79, 125, 205, 289, 299, 301-302, 353-355, 397, 500 and 511 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In one embodiment, the compound of formula (IF) is Compound 205 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compound of this embodiment was tested in the CK1δ inhibition assay as described herein and exhibited inhibition of greater than 50%.
- According to a sixth aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (IG) or a pharmaceutically acceptable salt or solvate thereof:
- wherein
Zg represents a bond, —C(R7g)(R8g)—, (CH2)2, —O—, —S—, —CH2—O—, —(CH2)2—O—, NR6g, —N(R6g)—C(R7g)(R8g)—, —N(R6g)—(CH2)2—, —N(R6g)—(CH2)3—, —CH2—N(R6g)—(CH2)2—, —N(R6g)—CO—, —CH2—NH—CO—(CH2)2—, —N(R6g)—CO—CH2—, ═N—, —C(H)(CN)—, —C(═N—NH—COC1-6 alkyl)-, —CH═C(R6g)—CO—, ═CH—, —N═CH—, —N═C(Me)—, —C(R6g)═CH—, —NH—CO—C(═CH-heteroaryl)-, —C═C(Me)2—, —CH═CH—CO—N(R6g)—, —CH═C(R6g)—NH—CO—, —CH═C(R6g)—CO—O—CH2—, —CS—S—CH2—, —NH—CS—NH—, —NH—CS—NH—CH2—, —NH—CS—NH—(CH2)2—, —CH2—N(CSNH2)—CH2—, —S—CH2—, —S—(CH2)2—O—, SO2, —NH—SO2—, —CH2—NH—SO2—, CO, —CH2—CO—, —(CH2)2—CO—, —O—CH2—CO—, —(CH2)2—CO—, COO, —COO—C(R7g)CO—, —CH═C(R5g)—CONH—CH2—, —CO—CH2—N(R6g)—CO—, —CO—CH2—C(R6g)—CH2—CO—, —CO—CH2—N(R6g)—CH2—, —CO—NH—N═C(R7g)—, —S—C(R6g)(R7g)—CO—, —S—CH2—CO—N(R6g)—, —S—CH2—CO—N(R6g)—CH2—, —SO2—N(R6g)—C(R7g)(R8g)—CONH—, —SO2—N(R6g)—CH(—CH2-aryl)—CONH—CH2—, —CH(—S—C1-6 alkyl)—C(Me)(OH)—, —CH2—C(R6g)(OH)—, —C(OH)(CH(Me)(C3-8 cycloalkyl))-CH2—, —C(OH)(R6g)—CH2—, —CH(Me)—NH—CO—CH2—, —CO—N(R6g)—CH2—, —CO—N(R6g)—CH2—CH2—, —CO—N(R6g)—CH2—CH2—CO—NH—CH2—, —CO—NH—C(—CONH2)═CH—, —CO—NH—CH(—CONH2)—CH2—, —CH2—C(H)(Me)—CH2—S—, —O—CH2—CO—NH—, —CH2—N(R6g)—CO—CH2—O, —N(R6g)—CO—CH2—O—, —C(H)(—CH2-aryl)-, —C(H)(—CH2-heteroaryl)-, —C(NH-aryl)═N—N═CH—, —C(NH-aryl)═N—N═CH—, —NH—N═C(-aryl)-, —NH—N═C(-aryl)-CO—, —NH—C(═N—CO—C1-6 alkyl)-NH—(CH2)2—, —C(—NH-aryl)=N—N═CH—, —NH—C(—NH-aryl)=N—CONH—, —C(═CH-aryl)-CONH—CH2—, —CH═C(R6g)—CONH—, —CH(—CH2-aryl)-NH—CO— or —CH(OH)—, wherein said aryl or heteroaryl groups of Zg may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, NO2 or hydroxyl groups;
R5g represents hydrogen, C1-6 alkyl or cyano;
R6g represents hydrogen, C1-6 alkyl, C1-6 alkoxy, cyano, C3-8 cycloalkyl, —CH2—C3-8 cycloalkyl, aryl, heteroaryl, —C1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R7g)(R8g)-heteroaryl, wherein said aryl groups of R6g may be optionally substituted by one or more halogen or C1-6 alkoxy groups;
R7g and R8g independently represent hydrogen or C1-6 alkyl;
R1g represents aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R1g may be substituted by one or more (e.g. 1, 2 or 3) R4g groups;
R4g represents halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C3-8 cycloalkyl, haloC1-6 alkyl, hydroxyl, C1-6 alkoxy, haloC1-6 alkoxy, —COOH, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —CONH2, —CH2—CONH2, —NH—C1-6 alkyl, —NH—C2-6 alkenyl, —NH—CO—C1-6 alkyl, —CO—NH—C1-6 alkyl, —O—CH2—CO—NH—C1-6 alkyl, —CH2—CH2—CO—NH—C1-6 alkyl, —S—C1-6 alkyl, —SO—C1-6 alkyl, —SO2—C1-6 alkyl, —SO2—NH—C1-6 alkyl, —S—CH2—CO—C2-6 alkenyl, —SO2—OH, amino, cyano, NO2, ═O, —CO—NH—(CH2)2)—OMe, —NH—C3-8 cycloalkyl, —CO-heterocyclyl, —CO-heteroaryl, —COO—(CH2)2-heterocyclyl, —OCH2-aryl, —OCH2-heteroaryl, —CH2—O—CO-aryl, —O-aryl, —NH—CO-heteroaryl, —NH—CO—CH2-aryl, aryl or heteroaryl groups, wherein said aryl, heterocyclyl or heteroaryl groups of R4g may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, ═S or hydroxyl groups and wherein said C1-6 alkyl or C2-6 alkenyl groups of R4g may be optionally substituted by one or more hydroxyl, amino, cyano, C1-6 alkoxy, CONH2 or —COO—C1-6 alkyl groups;
t represents an integer from 0 to 3;
R2g represents halogen, haloC1-6 alkyl, C1-6 alkyl, hydroxyl, C1-6 alkoxy, —CH2—S—C1-6 alkyl, —S—C2-6 alkynyl, amino, cyano, NO2, ═O, ═S, —SO2—C1-6 alkyl, —CONH2, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —NH—C1-6 alkyl, —NH—CO—C1-6 alkyl, —NH—CO—CH═CH—CH2—N(Me)2, C1-6 alkyl, —CO—NH—C1-6 alkyl, —CO—NH—CH(Me)—COOH, —S—CH2—CO—N(Et)2, —NH—(CH2)2—OH, —NH—(CH2)3—OH, —NH—CH(Et)—CH2—OH, —CO—NH—(CH2)3—OH, —CH(CH2OH)2 or —S—CH2—CO—NH—CO—NH—C1-6 alkyl, wherein said C1-6 alkyl groups of R2g may be optionally substituted by one or more hydroxyl groups; with the proviso that the compound is other than compound number 789, 839 and 924. - In one embodiment, the compound of formula (IG) is selected from any of compounds: 98-101, 248, 257, 259-260, 266, 271, 380, 394, 449, 461, 464, 477, 502-504, 523, 530, 535, 574, 673, 713, 779, 788, 825, 881-882, 935, 956, 968, 972 and 996 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a further embodiment, the compound of formula (IG) is selected from any of compounds:
- 98, 101, 248, 257, 259-260, 266, 271, 380, 394 and 530 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In a yet further embodiment, the compound of formula (IG) is compound 825 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In one embodiment, the compound of formula (IG) is selected from any of compounds: 825, 881-882, 935, 956, 968, 972 and 996 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds of this embodiment were tested in the CK1 O inhibition assay as described herein and exhibited inhibition of greater than 5%.
- In one embodiment, the compound of formula (IG) is Compound 972 as described herein or a pharmaceutically acceptable salt or solvate thereof. The compound of this embodiment was tested in the CK1O inhibition assay as described herein and exhibited inhibition of greater than 50%.
- According to a seventh aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (IH) or a pharmaceutically acceptable salt or solvate thereof:
- wherein
“Het H1” and “Het H2” independently represent a 5 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S;
Zh represents a bond, —C(R7h)(R8h)—, (CH2)2, —O—, —S—, —CH2—O—, —(CH2)2—O—, NR6h, —N(R6h)—C(R6h)(R7h)—, —N(R6h)—(CH2)2—, —N(R6h)—(CH2)3—, —CH2—N(R6h)—(CH2)2—, —N(R6h)—CO—, —CH2—NH—CO—(CH2)2—, —N(R6h)—CO—CH2—, ═N—, —C(H)(CN)—, —C(═N—NH—COC1-6alkyl)-, —CH═C(R6h)—CO—, ═CH—, —N═CH—, —N═C(Me)—, —C(R6h)═CH—, —NH—CO—C(═CH-heteroaryl)-, —C═C(Me)2—, —CH═CH—CO—N(R6h)—, —CH═C(R6h)—NH—CO—, —CH═C(R6h)—CO—O—CH2—, —CS—S—CH2—, —NH—CS—NH—, —NH—CS—NH—CH2—, —NH—CS—NH—(CH2)2—, —CH2—N(CSNH2)—CH2—, —S—CH2—, —S—(CH2)2—O—, SO2, —NH—SO2—, —CH2—NH—SO2—, CO, —CH2—CO—, —(CH2)2—CO—, —O—CH2—CO—, —(CH2)2—CO—, COO, —COO—C(R7h)CO—, —CH═C(R5h)—CONH—CH2—, —CO—CH2—N(R6h)—CO—, —CO—CH2—C(R6h)—CH2—CO—, —CO—CH2—N(R6h)—CH2—, —CO—NH—N═C(R7h)—, —S—CH2—CO—, —S—CH2—CO—N(R6h)—, —S—CH2—CO—N(R6h)—CH2—, —SO2—N(R6h)—C(R7h)(R8h)—CONH—, —SO2—N(R6h)—CH(—CH2-aryl)—CONH—CH2—, —CH(—S—C1-6 alkyl)-C(Me)(OH)—, —CH2—C(R6h)(OH)—, —C(OH)(CH(Me)(C3-8 cycloalkyl))-CH2—, —C(OH)(R6h)—CH2—, —CH(Me)—NH—CO—CH2—, —CO—N(R6h)—CH2—, —CO—N(R6h)—CH2—CH2—, —CO—N(R6h)—CH2—CH2—CO—NH—CH2—, —CO—NH—C(—CONH2)═CH—, —CO—NH—CH(—CONH2)—CH2—, —CH2—C(H)(Me)—CH2—S—, —O—CH2—CO—NH—, —CH2—N(R6h)—CO—CH2—O—, —N(R6h)—CO—CH2—O—, —C(H)(—CH2-aryl)-, —C(H)(—CH2-heteroaryl)-, —C(NH-aryl)═N—N═CH—, —C(NH-aryl)═N—N═CH—, —NH—N═C(-aryl)-, —NH—N═C(aryl)-CO—, —NH—C(═N—CO—C1-6 alkyl)-NH—(CH2)2—, —C(—NH-aryl)=N—N═CH—, —NH—C(—NH-aryl)=N—CONH—, —C(═CH-aryl)-CONH—CH2—, —CH═C(R6h)—CONH—, —CH(—CH2-aryl)-NH—CO— or —CH(OH)—, wherein said aryl or heteroaryl groups of Zh may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, NO2 or hydroxyl groups;
R5h represents hydrogen, C1-6 alkyl or cyano;
R6h represents hydrogen, C1-6 alkyl, C1-6 alkoxy, cyano, C3-8 cycloalkyl, —CH2—C3-8 cycloalkyl, aryl, heteroaryl, —C1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R7h)(R8h)-heteroaryl, wherein said aryl groups of R6h may be optionally substituted by one or more halogen or C1-6 alkoxy groups;
R7h and R8h independently represent hydrogen or C1-6 alkyl;
R1h and R2h independently represent halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C3-8 cycloalkyl, haloC1-6 alkyl, hydroxyl, C1-6 alkoxy, —O—C1-6 alkenyl, haloC1-6 alkoxy, —COOH, CO—C1-6 alkyl, —COO—C1-6 alkyl, —CONH2, —CH2—CONH2, —NH—C1-6 alkyl, —NH—C2-6 alkenyl, NH—CO—C1-6 alkyl, —CO—NH—C1-6 alkyl, —O—CH2—CO—NH—C1-6 alkyl, —CH2—CH2—CO—NH—C1-6 alkyl, —S—C1-6 alkyl, —SO—C1-6 alkyl, —SO2C1-6 alkyl, —SO2—NH—C1-6 alkyl, —S—CH2—CO—C2-6 alkenyl, —SO2—OH, amino, cyano, NO2, ═O, —CO—NH—(CH2)2)—OMe, —NH—C3-8 cycloalkyl, —CO-heterocyclyl, —CO-heteroaryl, —COO—(CH2)2-heterocyclyl, —OCH2-aryl, —OCH2-heteroaryl, —CH2—O—CO-aryl, —O-aryl, —NH—CO-heteroaryl, —NH—CO—CH2-aryl, aryl or heteroaryl groups, wherein said aryl, heterocyclyl or heteroaryl groups of R1h and R2h may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, ═S or hydroxyl groups and wherein said C1-6 alkyl or C2-6 alkenyl groups of R1h and R2h may be optionally substituted by one or more hydroxyl, amino, cyano, C1-6 alkoxy, CONH2 or —COO—C1-6 alkyl groups;
u and v independently represent an integer from 0 to 3;
with the proviso that the compound is other than compound number 757 and 878. - In one embodiment, the compound of formula (IH) is selected from any of compounds:
- 395, 433, 689 and 786 as described herein or a pharmaceutically acceptable salt or solvate thereof.
- In the present context, the term “pharmaceutically acceptable salt” is intended to indicate salts which are not harmful to the patient. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts and pharmaceutically acceptable akaline addition salts. Acid addition salts include salts of inorganic acids as well as organic acids.
- Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
- Representative examples of alkaline salts include, for example, sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine, N-methylglucamine.
- According to the invention, the compounds of formulae (IA)-(IH) can be in racemic forms, as well as in the form of pure enantiomers or non racemic (scalemic) mixture of enantiomers, including when the compounds of formulae (IA)-(IH) have more than one stereogenic centre.
- In case the compounds of formulae (IA)-(IH) have unsaturated carbon carbon double bonds, both the cis (Z) and trans (E) isomers and their mixtures belong to the invention.
- References herein to “halogen” means a fluorine, chlorine, bromine or iodine atom.
- References herein to “C1-6 alkyl” means any linear, branched hydrocarbon groups having 1 to 6 carbon atoms, or cyclic hydrocarbon groups having 3 to 6 carbon atoms. Representative examples of such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, n-pentyl, isopentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. References to “haloC1-6 alkyl” mean a C1-6 alkyl group substituted by one or more halogen atoms as herein defined.
- References herein to “C1-6 alkylene” means a saturated divalent hydrocarbon chain having the specified number of member atoms. For example, C1-6 alkylene refers to a bond or an alkylene group having from 1 to 6 member atoms. Alkylene groups may be straight or branched. Representative branched alkylene groups have one or two branches. Alkylene includes methylene, ethylene, propylene (n-propylene and isopropylene) and butylene (n-butylene, isobutylene, and t-butylene).
- References herein to “C2-6 alkenyl” means any linear, branched hydrocarbon groups of 2 to 6 carbon atoms, or cyclic hydrocarbon group having 3 to 6 carbon atoms having at least one double bond. Representative examples of such alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl.
- References herein to “C2-6 alkynyl” means any linear, or branched hydrocarbon groups of 2 to 6 carbon atoms, having at least one triple bond. Representative examples of such alkynyl groups include ethynyl, propargyl and butynyl.
- References herein to ‘C1-6 alkoxy’ means an —O—C1-6 alkyl group wherein C1-6 alkyl is as defined herein. Examples of such groups include methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy and the like.
- References herein to ‘C3-8 cycloalkyl’ means a saturated monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl and the like.
- References herein to ‘aryl’ means a C6-12 monocyclic or bicyclic hydrocarbon ring wherein at least one ring is aromatic. Examples of such groups include phenyl, indyl or naphthyl and the like.
- References herein to “heteroatom” means a nitrogen, sulphur, or oxygen atom.
- References herein to “heterocyclyl” means a saturated or unsaturated non-aromatic ring containing from 1 to 4 heteroatoms as member atoms in the ring. Heterocyclyl groups containing more than one heteroatom may contain different heteroatoms. Heterocyclyl groups may be optionally substituted with one or more substituents as defined herein. Heterocyclyl groups are monocyclic ring systems or fused bicyclic or polycyclic ring systems or bicyclic structures known as heterocyclic “Spiro” ring systems. In certain embodiments, heterocyclyl is saturated. In other embodiments, heterocyclyl is unsaturated and non-aromatic. Non-limiting examples of monocyclic heterocyclyl ring systems include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, pyranyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothienyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-oxathiolanyl, 1 ,3-oxathianyl, 1,3-dithianyl, and azetidinyl.
- References herein to “heteroaryl” means an aromatic ring containing from 1 to 4 heteroatoms as member atoms in the ring. Heteroaryl groups containing more than one heteroatom may contain different heteroatoms. Heteroaryl groups may be optionally substituted with one or more substituents as defined herein. Heteroaryl groups are monocyclic ring systems or are fused bicyclic or polycyclic ring systems. Monocyclic heteroaryl rings have 5 or 6 member atoms. Bicyclic heteroaryl rings have from 7 to 11 member atoms. Bicyclic heteroaryl rings include those rings wherein phenyl and a monocyclic heterocyclyl ring are attached forming a fused bicyclic ring system, and those rings wherein a monocyclic heteroaryl ring and a monocyclic cycloalkyl, cycloalkenyl, heterocyclyl, or heteroaryl ring are attached forming a fused bicyclic ring system. Non-limiting examples of heteroaryl includes pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furanyl, furazanyl, thienyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, indolyl, isoindolyl, indolizinyl, indazolyl, purinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pteridinyl, cinnolinyl, benzimidazolyl, benopyranyl, benzoxazolyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzothienyl, furopyridinyl, and napthyridinyl.
- References herein to “heterocyclic ring system” mean either a heterocyclyl ring system or a heteroaryl ring system as hereinbefore defined.
- Representative compounds of the invention include compounds 1-1002 as set forth below:
-
-
Lengthy table referenced here US20160354375A1-20161208-T00001 Please refer to the end of the specification for access instructions. - According to a further aspect of the invention, there is provided a compound of any one of formulae (IA)-(1H) for use as a casein kinase 1 delta (CK1δ) inhibitor in the treatment of a neurodegenerative disorder, such as tauopathies.
- According to a further aspect of the invention, there is provided a compound of formula 1-37, 39-53, 55-137, 139-160, 162-211, 213-242, 244-249, 251-272, 274-285, 287-372, 374-377, 379-414, 416-440, 442-457, 459-466, 468-479, 481-495, 497-532, 534-543, 545-570, 572-576, 578, 581-584, 586, 588-599, 603-628, 630-635, 637-646, 650-657, 659-661, 663-677, 679, 681-683, 686-702, 704-725, 727-746, 748-750, 752-756, 758-759, 761-768, 770-777, 779-782, 784-788, 780-801, 804-805, 807-823, 825-838, 840-860, 862-866, 868-870, 872, 875, 881-882, 885-886, 888-890, 894-894, 904-905, 931, 933, 935, 941, 946-958, 964-1000 and 1002 or a pharmaceutically acceptable salt or solvate thereof for use as a casein kinase 1 delta (CK1δ) inhibitor in the treatment of a neurodegenerative disorder, such as tauopathies.
- Compounds of formula 1-1002 are either commercially available or may be prepared in accordance with known synthetic procedures.
- According to a further aspect of the invention there is provided a pharmaceutical composition comprising any one of the compounds of formulae (IA)-(IH) for use in the treatment of a neurodegenerative disorder, such as tauopathies.
- The pharmaceutical compositions of the invention may comprise, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those of ordinary skill in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e. g., oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.
- Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
- For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of ordinary skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
- The compounds of formulae (IA)-(IH) are believed to be casein kinase 1 delta (CK1δ) inhibitors. Certain compounds of formulae (IA)-(IH) have inhibitory activity of greater than 5%, in particular greater than 10%, more particularly greater than 25%, yet more particularly greater than 50%, especially greater than 75%, such as greater than 90%. Such compounds may be useful in the treatment in neurodegenerative disorders such as tauopathies. Tauopathies are conditions which are characterised by neurofibrillary tangles or aggregates of the tau protein. Tauopathies are a recognised class of conditions known to those skilled in the art and include Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, multisystem atrophy (MSA), neurobasal degeneration with iron accumulation, type 1 (Hallervorden-Spatz), argyrophilic grain dementia, Down's syndrome, diffuse neurofibrillary tangles with calcification, dementia pugilistica, Gerstmann-Straussler-Scheinker disease, myotonic dystrophy, Niemann-Pick disease type C, progressive subcortical gliosis, prion protein cerebral amyloid angiopathy, tangle only dementia, postencephalitic parkinsonism, subacute sclerosing panencephalitis, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis/parkinsonism-dementia complex, non-Guamanian motor neuron disease with neurofibrillary tangles/dementia, and Parkinson's disease. The intracellular tau deposits are usually neuronal or glial and are filamentous and generally in a hyperphosphorylated state as compared to the level of phosphorylation in tau from control human brain. In the case of AD, this hyperphosphorylated tau is often referred to a paired helical filament tau (PHF) tau because it is derived from the PHF. In one embodiment, the tauopathy comprises Alzheimer's disease.
- According to a further aspect of the invention, there is provided a method of treating a neurodegenerative disorder, such as tauopathies, which comprises administering a therapeutically effective amount of a compound of formulae (1A)-(1 H).
- CK1δ Inhibition Assay The compounds of the invention may be tested for inhibition of casein kinase 1 delta (CK1δ) in accordance with the assay protocols described in US 2010/0152157, EP 1,636,375 or Hanger et al (2007) J. Biol. Chem. 282, 23645-23654. In particular, the assay was conducted in accordance with the following protocol:
- Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO
- It should be noted that required cofactors are added individually to each kinase reaction.
- 1. Prepare indicated substrate in freshly prepared Base Reaction Buffer as described above
- 2. Deliver any required cofactors to the substrate solution
- 3. Deliver indicated kinase into the substrate solution and gently mix
- 4. Deliver compounds in DMSO into the kinase reaction mixture
- 5. Deliver 33P-ATP (specific activity 0.01 μCi/μl final) into the reaction mixture to initiate the reaction
- 6. Incubate kinase reaction for 120 min. at room temperature
- 7. Reactions are spotted onto P81 ion exchange paper (Whatman # 3698-915)
- 8. Wash filters extensively in 0.75% Phosphoric acid
- CK1d—Genbank Accession # NP_620693
- Recombinant human full-length construct. GST-tagged, expressed in insect cells.
- Final concentration in assay =4 nM
- Substrate: CKltide
- Substrate sequence: [KRRRAL[pS]VASLPGL]
- Final substrate concentration in assay=20 μM
- It should be noted that no additional cofactors are added to the reaction mixture.
- Compounds 10, 25, 30, 42, 45, 205, 223, 240, 281-282, 288, 314, 321, 324-325, 336, 374, 391, 405, 439, 465, 506, 512, 567, 583, 611-616, 619, 623-624, 626, 631, 633, 639-640, 646, 654, 656, 660-661, 663, 668, 670, 672, 675-677, 682-683, 696-697, 700, 705-706, 717, 723, 727, 730, 736-737, 740, 748, 753-754, 756, 759, 761, 765-766, 768, 770, 780, 790, 797, 784, 808-810, 819-820, 822-823, 825, 830, 832-834, 842, 844, 847, 851, 856, 859-860, 863, 868-870, 872, 875, 881-882, 885-886, 888-890, 894, 931, 933, 935, 941, 946-958, 964-1000 and 1002 were tested in the CK1δ inhibition assay and exhibited inhibition of greater than 5%.
- In particular, compounds 10, 42, 45, 205, 240, 324-325, 405, 654, 656, 682, 700, 754, 766, 847, 856, 859, 863, 894, 931, 947-949, 951-952, 954, 964, 967, 972, 978-979, 986-987, 990, 997 and 999 exhibited inhibition of greater than 50%.
- Yet more particularly, compounds 10, 324, 654, 856, 859, 931, 947, 952, 987, 990 and 999 exhibited inhibition of greater than 90%.
-
-
LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20160354375A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).
Claims (15)
1-29. (canceled)
30. A method of treating a neurodegenerative disorder in a subject, comprising administering an effective amount of a casein kinase 1 delta (ck1δ) inhibitor compound of formula (IC), or a pharmaceutically acceptable salt or solvate thereof:
wherein
“Het C” represents pyridinyl, pyrimidinyl or quinazolinyl;
Xc and Yc independently represent a bond or NH;
R1c and R2c independently represent phenyl, benzodioxinyl, pyridinyl, pyrazol-4-yl, thiophenyl or benzoxazolyl, wherein R1c and R2c may be substituted by one or more R4c groups;
R4c represents selected from hydroxyl, methoxy or —CONH2;
p represents an integer from 0 to 2;
R3c represents halogen, halo C1-6 alkyl, C1-6 alkyl, hydroxyl, C1-6 alkoxy, —S—C1-6 alkyl, —CH2—S—C1-6 S—C1-6 alkyl, —S—C2-6 alkynyl, amino, cyano, NO2, ═O, ═S, —SO2—C1-6 alkyl, —CONH2, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —NH—C1-6 alkyl, —NH—CO—C1-6 alkyl, —NH—CO—CH═CH—CH2—N(Me)2, C1-6 alkyl, —CO—NH—C1-6 alkyl, —CO—NH—CH(Me)—COOH, —S—CH2—CO—N(Et)2, —NH—(CH2)2—OH, —NH—(CH2)3—OH, —NH—CH(Et)—CH2—OH, —CO—NH—(CH2)3—OH, —CH(CH2OH)2 or —S—CH2—CO—NH—CO—NH—C1-6 alkyl, aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein said aryl, heterocyclyl or heteroaryl groups of R3c may be optionally substituted by one or more R4c groups and wherein said C1-6 alkyl groups of R3c may be optionally substituted by one or more hydroxyl groups;
with the proviso that the compound is other than compound number 867.
31. The method of claim 30 , wherein “Het C” represents quinazolinyl.
32. The method of claim 30 , wherein one of Xc and Ycrepresents a bond and the other represents NH.
33. The method of claim 30 , wherein R1c and R2c independently represent phenyl, pyridinyl, pyrazol-4-yl or thiophenyl, wherein R1c and R2c may be substituted by one or more R4c groups selected from hydroxyl, methoxy or —CONH2.
34. The method of claim 33 , wherein R1C and R2c independently represent unsubstituted phenyl, unsubstituted pyridinyl or pyrazol-4-yl.
35. The method of claim 30 , wherein p is 0.
36. The method of claim 30 , wherein R3c represents ═O, cyano or pyridinyl.
37. The method of claim 36 , wherein p is 1 and R3c represents pyridinyl.
38. The method of claim 36 , wherein p is 2 and R3c represents ═O or cyano.
39. The method of claim 30 , wherein the compound of formula (IC) is selected from the group consisting of:
2-Phenyl-N-(pyridin-4-yl)quinazolin-4-amine (Compound 700);
N-(2,3-Dihydro-1,4-benzadioxin-6-yl)-2-phenylquinazolin-4-amine (Compound 868);
4-{([2-(Thiophen-3-yl)quinazolin-4-yl]amino}benzamide (Compound 870);
2-Phenyl-N-(1H-pyrazol-4-yl)quinazolin-4-amine (Compound 894);
2-[2-Methyl-4-(pyridin-4-yl)pyrimidin-5-yl]-1,3-benzoxazole (Compound 949);
2-[2-(Pyridin-2-yl)-4-(pyridin-4-yl)pyrimidin-5-yl]-1,3-benzoxazole (Compound 950);
5-(1,3-Benzoxazol-2-yl)-2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile (Compound 951);
4-[(2-Phenylquinazolin-4-yl)amino]phenol (Compound 957);
N-(4-Methoxyphenyl)-2-(thiophen-2-yl)quinazolin-4-amine (Compound 973);
N-(4-Methoxyphenyl)-2-(pyridin-2-yl)quinazolin-4-amine (Compound 977);
6-Phenyl-2-(pyridin-2-yl)-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 986); and 4-[(2-Phenylquinazolin-4-yl)amino]benzamide (Compound 993);
or a pharmaceutically acceptable salt or solvate thereof.
40. The method of claim 39 , wherein the compound of formula (IC) is 2-Phenyl-N-(pyridin-4-yl)quinazolin-4-amine (Compound 700) or a pharmaceutically acceptable salt or solvate thereof.
41. The method of wherein the neurodegenerative disorder is a tauopathy,
42. The method of claim 41 , wherein the tauopathy is selected from Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, multisystem atrophy (MSA), neuobasal degeneration with iron accumulation, type 1 (Hallervorden-Spatz), argyrophilic grain dementia, Down's syndrome, diffuse neurofibrillary tangles with calcification, dementia pugilistica, Gerstmann-Straussler-Scheinker disease, myotonic dystrophy, Niemann-Pick disease type C, progressive subcortical gliosis, prion protein cerebral amyloid angiopathy, tangle only dementia, postencephalitic parkinsonism, subacute sclerosing panencephalitis, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis/parkinsonism-dementia complex, non-Guamanian motor neuron disease with neurofibrillary tangles/dementia, and Parkinson's disease.
43. The method of claim 42 , wherein the tauopathy comprises Alzheimer's disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/171,582 US20160354375A1 (en) | 2010-12-14 | 2016-06-02 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1021161.3 | 2010-12-14 | ||
GBGB1021161.3A GB201021161D0 (en) | 2010-12-14 | 2010-12-14 | Casein kinase 1delta (CK1Delta) inhibitors |
GB1109162.6 | 2011-06-01 | ||
GBGB1109162.6A GB201109162D0 (en) | 2011-06-01 | 2011-06-01 | Casein kinase 1Delta (CK1Delta) inhibitors |
PCT/GB2011/052475 WO2012080729A2 (en) | 2010-12-14 | 2011-12-14 | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
US201313993288A | 2013-09-19 | 2013-09-19 | |
US15/171,582 US20160354375A1 (en) | 2010-12-14 | 2016-06-02 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/993,288 Division US20140031547A1 (en) | 2010-12-14 | 2011-12-14 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
PCT/GB2011/052475 Division WO2012080729A2 (en) | 2010-12-14 | 2011-12-14 | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160354375A1 true US20160354375A1 (en) | 2016-12-08 |
Family
ID=45444638
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/993,303 Abandoned US20140018540A1 (en) | 2010-12-14 | 2011-12-14 | Casein kinase 1delta (ck 1delta) inhibitors |
US13/993,288 Abandoned US20140031547A1 (en) | 2010-12-14 | 2011-12-14 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
US14/677,273 Active US9789111B2 (en) | 2010-12-14 | 2015-04-02 | Casein kinase 1δ (CK 1δ) inhibitors |
US14/842,155 Active US9763947B2 (en) | 2010-12-14 | 2015-09-01 | Casein kinase 1delta (CK1delta) inhibitors |
US15/171,582 Abandoned US20160354375A1 (en) | 2010-12-14 | 2016-06-02 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/993,303 Abandoned US20140018540A1 (en) | 2010-12-14 | 2011-12-14 | Casein kinase 1delta (ck 1delta) inhibitors |
US13/993,288 Abandoned US20140031547A1 (en) | 2010-12-14 | 2011-12-14 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
US14/677,273 Active US9789111B2 (en) | 2010-12-14 | 2015-04-02 | Casein kinase 1δ (CK 1δ) inhibitors |
US14/842,155 Active US9763947B2 (en) | 2010-12-14 | 2015-09-01 | Casein kinase 1delta (CK1delta) inhibitors |
Country Status (10)
Country | Link |
---|---|
US (5) | US20140018540A1 (en) |
EP (3) | EP2651404B1 (en) |
JP (4) | JP5937102B2 (en) |
CN (3) | CN104906103B (en) |
AU (2) | AU2011343039B2 (en) |
CA (1) | CA2818903C (en) |
DK (1) | DK2835131T3 (en) |
ES (2) | ES2553610T3 (en) |
HK (2) | HK1190622A1 (en) |
WO (2) | WO2012080727A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020051206A1 (en) * | 2018-09-04 | 2020-03-12 | Brown University | Compositions and methods for the modulation of crfbp and the treatment of alcoholism |
US11084807B2 (en) | 2016-08-18 | 2021-08-10 | Vidac Pharama Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
US11161850B2 (en) | 2018-07-05 | 2021-11-02 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
US11390624B2 (en) | 2019-01-29 | 2022-07-19 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
US11613548B2 (en) | 2021-02-19 | 2023-03-28 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors |
US11673894B2 (en) | 2018-02-27 | 2023-06-13 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
Families Citing this family (194)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3219705T3 (en) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
AU2009204483B2 (en) | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
AU2010273816B2 (en) | 2009-06-29 | 2015-07-09 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
WO2011123609A1 (en) * | 2010-03-31 | 2011-10-06 | Glaxo Group Limited | Imidazolyl-imidazoles as kinase inhibitors |
WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
CN104906103B (en) * | 2010-12-14 | 2018-05-18 | 电泳有限公司 | Casein kinase 1 δ (CK1 δ) inhibitor |
EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
BR112013017670B1 (en) | 2011-01-10 | 2022-07-19 | Infinity Pharmaceuticals, Inc | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
AR087701A1 (en) | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | PIRAZOL DERIVATIVES WITH SGLT1 INHIBITING ACTIVITY |
AR087760A1 (en) | 2011-09-02 | 2014-04-16 | Incyte Corp | HETEROCICLILAMINAS AS PI3K INHIBITORS |
CN103842356B (en) | 2011-10-07 | 2017-03-15 | 武田药品工业株式会社 | For treating 1 aryl carbonyl, the 4 Oxypertine compound of neurodegenerative disease |
JP6020459B2 (en) | 2011-10-18 | 2016-11-02 | アステラス製薬株式会社 | Bicyclic heterocyclic compounds |
AR090037A1 (en) | 2011-11-15 | 2014-10-15 | Xention Ltd | DERIVATIVES OF TIENO AND / OR FURO-PYRIMIDINES AND PYRIDINES INHIBITORS OF THE POTASSIUM CHANNELS |
AU2012345746B2 (en) | 2011-12-01 | 2016-12-08 | Chemocentryx, Inc. | Substituted anilines as CCR(4) antagonists |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
SG10201610416TA (en) | 2012-06-13 | 2017-01-27 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
CN104364239B (en) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | Diaza spiro cycloalkane and azaspiro alkane |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
EP2871179A4 (en) | 2012-07-03 | 2016-03-16 | Ono Pharmaceutical Co | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
WO2014009891A1 (en) * | 2012-07-11 | 2014-01-16 | Piramal Enterprises Limited | Heterocyclic compounds for use in the treatment of cancers |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014031732A2 (en) | 2012-08-22 | 2014-02-27 | Cornell University | Methods for inhibiting fascin |
US9328078B2 (en) * | 2012-08-24 | 2016-05-03 | Treventis Corporation | Benzofurazan anti-amyloid compounds and methods |
CN102850341B (en) * | 2012-09-05 | 2015-02-18 | 浙江工业大学 | Thiadiazole compound, preparation method and applications thereof |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
MX368615B (en) | 2012-09-25 | 2019-10-09 | Hoffmann La Roche | New bicyclic derivatives. |
CN103739594A (en) * | 2012-10-17 | 2014-04-23 | 南京大学 | Schiff base derivatives containing pyrazine ring and triazole structure and preparation method of the derivatives |
CN105143206B (en) | 2012-11-27 | 2019-01-15 | 托马斯·黑勒戴药物研究基金会 | Pyrimidine -2,4- diamine derivative for treating cancer |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US20150329540A1 (en) * | 2012-12-28 | 2015-11-19 | Shin Nippon Biomedical Laboratories, Ltd. | Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent |
WO2014124458A1 (en) | 2013-02-11 | 2014-08-14 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases |
AR095079A1 (en) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO |
JP2016520532A (en) | 2013-03-15 | 2016-07-14 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | Benzimidazole derivatives and uses thereof |
US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
US9776996B2 (en) | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as fgfr inhibitors |
US9797882B2 (en) | 2013-07-09 | 2017-10-24 | The Translational Genomics Research Institute | Method of screening for a compound for inhibitory activity of FN14-tweak interaction |
WO2015006508A2 (en) | 2013-07-09 | 2015-01-15 | The Translational Genomics Research Institute | Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14 |
TWI649308B (en) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | Quinoline derivative |
GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
RU2570907C2 (en) * | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | 3-acylaminopyridin derivatives, applicable as serine-threonine proteinkinase gsk3b inhibitors, as medications for type ii diabetes treatment |
PL3071206T3 (en) | 2013-11-22 | 2022-01-17 | CL BioSciences LLC | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
HUE036117T2 (en) | 2013-11-26 | 2018-06-28 | Hoffmann La Roche | Octahydro-cyclobuta [1,2-c;3,4-c']dipyrrole derivatives as autotaxin inhibitors |
GB201321738D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
EP3091984B1 (en) * | 2014-01-09 | 2020-04-22 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Substituted benzoxazine and related compounds |
CR20160348A (en) | 2014-01-29 | 2017-04-28 | Glaxosmithline Intellectual Property Dev Ltd | COMPOUNDS |
CN105980388B (en) | 2014-01-29 | 2018-01-16 | 葛兰素史密斯克莱知识产权发展有限公司 | Compound |
AU2015217152A1 (en) | 2014-02-11 | 2016-08-11 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ES2672797T3 (en) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
KR102421235B1 (en) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Cyclopropylamines as lsd1 inhibitors |
CR20160395A (en) | 2014-02-13 | 2016-12-20 | Incyte Corp | CYCLOPROPILAMINS AS INHIBITORS OF LSD1 |
JP6691869B2 (en) | 2014-02-20 | 2020-05-13 | コーネル ユニヴァーシティー | Compounds and methods for inhibiting fascin |
SI3110812T1 (en) * | 2014-02-27 | 2019-08-30 | Treventis Corporation | Anti-amyloid compounds containing benzofurazan |
CN106029667B (en) | 2014-03-26 | 2019-08-23 | 豪夫迈·罗氏有限公司 | Condensed [1,4] diaza * compound as autocrine motility factor (ATX) and lysophosphatidic acid (LPA) production inhibitor |
MA39792B1 (en) | 2014-03-26 | 2019-12-31 | Hoffmann La Roche | Bicyclic compounds as inhibitors of autotaxin (atx) and lysophosphatidic acid (lpa) production |
CN106164059A (en) * | 2014-04-11 | 2016-11-23 | 爱默蕾大学 | With agedoite endopeptidase (AEP) inhibitor and the compositions related treatment to neurodegenerative diseases |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9840482B2 (en) * | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
ES2759246T3 (en) * | 2014-04-23 | 2020-05-08 | Dart Neuroscience Cayman Ltd | [1,2,4] Triazolo [1,5-a] pyrimidinyl-7-yl compounds substituted as PDE2 inhibitors |
WO2015170218A1 (en) | 2014-05-07 | 2015-11-12 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
CN104059060B (en) * | 2014-05-30 | 2017-08-01 | 西安交通大学 | A kind of ketones derivant of 5 (methylene of 1H indoles 3) 1,3 thiazolidine 4 and its synthetic method and application |
JP6635949B2 (en) | 2014-06-04 | 2020-01-29 | トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング | MTH1 inhibitors for the treatment of inflammatory and autoimmune diseases |
CA2949785A1 (en) | 2014-06-04 | 2015-12-10 | Thomas Helledays Stiftelse For Medicinsk Forskning | Mth1 inhibitors for treatment of cancer |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
BR112017001221A2 (en) | 2014-07-31 | 2017-11-28 | Merck Patent Gmbh | indolizine derivatives that are applicable to neurodegenerative diseases |
WO2016022465A1 (en) | 2014-08-04 | 2016-02-11 | Drexel University | Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same |
JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
CN107250113B (en) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | The eutectic of the regulator of cystic fibrosis transmembrane conductance regulator |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
WO2016073424A1 (en) | 2014-11-05 | 2016-05-12 | Dart Neuroscience, Llc | Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors |
ES2749726T3 (en) | 2014-12-25 | 2020-03-23 | Ono Pharmaceutical Co | Quinoline derivative |
GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
MX2020004108A (en) | 2015-02-20 | 2022-01-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors. |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
PT3262046T (en) | 2015-02-27 | 2020-12-24 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
EP3273955A4 (en) | 2015-03-23 | 2019-05-01 | The University of Melbourne | Treatment of respiratory diseases |
MY191796A (en) | 2015-04-03 | 2022-07-15 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
MA41898A (en) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | BICYCLIC QUINAZOLINONE DERIVATIVES |
PT3288933T (en) * | 2015-04-30 | 2021-11-29 | Musc Found For Res Dev | Oxindole compounds and pharmaceutical compositions thereof |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
GB201508276D0 (en) | 2015-05-14 | 2015-06-24 | Electrophoretics Ltd | A casein kinase 1 delta inhibitor |
BR112017025851A2 (en) * | 2015-06-01 | 2018-10-16 | Bantam Pharmaceutical, Llc | substituted pyrazole and pyrrol compounds and methods for using them for inhibition of translation initiation and treatment of related diseases and disorders |
WO2016202756A1 (en) | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
WO2016202758A1 (en) | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
US10167270B2 (en) | 2015-07-01 | 2019-01-01 | Northwestern University | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity |
CN110402244B (en) | 2015-08-12 | 2023-02-03 | 因赛特公司 | Salts of LSD1 inhibitors |
CN105061462B (en) * | 2015-08-18 | 2017-05-24 | 沈阳药科大学 | Tetrahydrobenzo [4,5] thieno [2,3-d] pyrimidines compound containing amide and application thereof |
UA123362C2 (en) | 2015-09-04 | 2021-03-24 | Ф. Хоффманн-Ля Рош Аг | Phenoxymethyl derivatives |
JP6469238B2 (en) | 2015-09-18 | 2019-02-13 | 科研製薬株式会社 | Biaryl derivative and medicament containing the same |
CA2991615A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
WO2017050791A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
CN107614505B (en) | 2015-09-24 | 2021-05-07 | 豪夫迈·罗氏有限公司 | Novel bicyclic compounds as dual ATX/CA inhibitors |
JP6740354B2 (en) | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | Activator of autophagy flow and clearance of protein aggregates containing phospholipase D and tau and method for treating proteinosis |
GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
WO2017063966A1 (en) | 2015-10-13 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds |
BR112018008431A2 (en) | 2015-11-02 | 2018-11-06 | Janssen Pharmaceutica Nv | [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compound |
CN106831569B (en) * | 2015-12-07 | 2020-07-17 | 成都海创药业有限公司 | Quinoline compound, preparation method thereof and application of quinoline compound as urate transporter inhibitor medicine |
WO2017106367A1 (en) * | 2015-12-15 | 2017-06-22 | D.E. Shaw Research, Llc | Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity |
WO2017133258A1 (en) * | 2016-02-04 | 2017-08-10 | 西华大学 | 1h-indazole derivative and use thereof as ido inhibitor |
CN107033087B (en) * | 2016-02-04 | 2020-09-04 | 西华大学 | 1H-indazole-4-amine compounds and use thereof as IDO inhibitors |
CN107840826B (en) * | 2016-09-19 | 2021-07-09 | 西华大学 | 1H-indazole derivatives and application thereof as IDO (intermediate bonded oxygen) inhibitor |
CN109414410B (en) | 2016-04-22 | 2022-08-12 | 因赛特公司 | Formulations of LSD1inhibitors |
CA3026149A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
CA3026784A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic pyrazine derivatives useful as shp2 inhibitors |
AU2017281797A1 (en) | 2016-06-24 | 2019-01-24 | Infinity Pharmaceuticals, Inc. | Combination therapies |
SG11201811161YA (en) | 2016-07-14 | 2019-01-30 | Pfizer | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
ES2901059T3 (en) * | 2016-08-09 | 2022-03-21 | Zincure Corp | Pharmaceutical composition for the treatment of stroke based on AMPK inhibition |
LT3507291T (en) | 2016-09-02 | 2021-09-10 | Cyclerion Therapeutics, Inc. | Fused bicyclic sgc stimulators |
CN106432235B (en) * | 2016-10-19 | 2018-02-02 | 南通大学 | Target CDK and DNA β carboline derivatives and preparation method thereof and medical usage |
MA46589A (en) | 2016-10-24 | 2019-08-28 | Yumanity Therapeutics Inc | COMPOUNDS AND USES OF THE LATEST |
EA039102B1 (en) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS |
EP3535268B1 (en) | 2016-11-02 | 2022-02-09 | Janssen Pharmaceutica NV | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
MY193511A (en) * | 2016-11-02 | 2022-10-17 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
WO2018089967A1 (en) | 2016-11-14 | 2018-05-17 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
US20190358238A1 (en) * | 2016-11-16 | 2019-11-28 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
JP6928096B2 (en) * | 2017-01-10 | 2021-09-01 | イーティーエイチ・チューリッヒ | Cytoprotective compounds and their use |
DK3571193T3 (en) | 2017-01-23 | 2022-01-17 | Cadent Therapeutics Inc | Potassium Channel Modulators |
CN106748969B (en) * | 2017-01-23 | 2019-06-18 | 南阳师范学院 | A kind of N- (4- benzyl piepridine base)-asafoetide amide compound, preparation method and its usage |
CN106831573B (en) * | 2017-01-23 | 2019-05-24 | 南阳师范学院 | (N-1,2,3,4- tetrahydro isoquinolyl)-asafoetide amide compound, preparation method and applications |
BR112019015352A2 (en) | 2017-01-26 | 2020-03-10 | Ono Pharmaceutical Co., Ltd. | QUINOLINE DERIVATIVE ETHANE-SULPHONATE SALT |
SG11201906681PA (en) | 2017-02-01 | 2019-08-27 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
CN109700794B (en) * | 2017-03-01 | 2021-01-08 | 浙江大学 | Hydrazone structure type androgen receptor antagonist and application thereof |
WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
AU2018233079B9 (en) | 2017-03-16 | 2021-07-22 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as dual ATX/CA inhibitors |
PL3448859T3 (en) | 2017-03-20 | 2020-02-28 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
EP3601239A4 (en) | 2017-03-23 | 2020-05-13 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
KR102648947B1 (en) | 2017-04-26 | 2024-03-18 | 바실리어 파마슈티카 인터내셔널 리미티드 | Process for manufacturing furazanobenzimidazole and its crystalline form |
EP3634406B1 (en) * | 2017-05-12 | 2023-09-06 | Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof |
AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
JOP20190282A1 (en) | 2017-06-09 | 2019-12-05 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
CN110997664A (en) * | 2017-06-14 | 2020-04-10 | 欧洲分子生物学实验室 | Benzofuran amides and heteroaromatic analogs thereof for use in therapy |
AU2018290225A1 (en) | 2017-06-21 | 2020-01-23 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
GB201710851D0 (en) * | 2017-07-06 | 2017-08-23 | Galápagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis |
CA3069138A1 (en) | 2017-07-10 | 2019-01-17 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
CA3069720A1 (en) | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
JP7159173B2 (en) * | 2017-09-11 | 2022-10-24 | 保土谷化学工業株式会社 | Compound having pyrimidine ring structure and organic electroluminescence device |
WO2019055877A1 (en) | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors |
WO2019074116A1 (en) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient |
MA50413A (en) | 2017-10-19 | 2020-08-26 | Amgen Inc | BENZIMIDAZOLE DERIVATIVES AND THEIR USES |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
CA3083368A1 (en) * | 2017-12-21 | 2019-06-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising a dementia |
SG11202004971YA (en) * | 2017-12-21 | 2020-06-29 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
EP3762383B1 (en) * | 2018-03-06 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Positive allosteric modulators of dopamine 1 receptor and method of use thereof |
EP3543231A1 (en) * | 2018-03-19 | 2019-09-25 | ETH Zurich | Compounds for treating cns- and neurodegenerative diseases |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
TW201946630A (en) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Salts of an FGFR inhibitor |
TWI815887B (en) * | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
SG11202012767UA (en) | 2018-06-29 | 2021-01-28 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
JP7422737B2 (en) * | 2018-08-06 | 2024-01-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 2-Arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases |
EP3843734A4 (en) | 2018-08-29 | 2022-05-25 | ChemoCentryx, Inc. | Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
CA3113233A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
JP7450610B2 (en) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Activation of pyruvate kinase R |
US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
CN109503563B (en) * | 2018-12-10 | 2020-05-12 | 济南大学 | Multifunctional acetylcholinesterase inhibitor and application thereof |
KR102128509B1 (en) * | 2018-12-19 | 2020-07-01 | 한국과학기술연구원 | Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof |
US20220073470A1 (en) * | 2019-01-04 | 2022-03-10 | Bellbrook Labs, Llc | Inhibitors of cgas activity as therapeutic agents |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
AR119731A1 (en) | 2019-05-17 | 2022-01-05 | Novartis Ag | NLRP3 INFLAMASOME INHIBITORS |
RS64931B1 (en) | 2019-06-18 | 2023-12-29 | Pfizer | Benzisoxazole sulfonamide derivatives |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
RU2746423C2 (en) * | 2019-09-02 | 2021-04-13 | Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") | Hepatitis b virus (hbv) inhibitor |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
WO2021096270A1 (en) * | 2019-11-14 | 2021-05-20 | 주식회사 진큐어 | Pharmaceutical composition for treating multiple sclerosis on basis of ampk inhibitory function and zinc homeostasis control function |
WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220124176A (en) | 2019-12-06 | 2022-09-13 | 버텍스 파마슈티칼스 인코포레이티드 | Substituted tetrahydrofuran as a modulator of sodium channels |
AR122711A1 (en) | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1d AND/OR KINASE 5 ACTIVIN RECEPTOR TYPE |
US20230339900A1 (en) * | 2020-09-17 | 2023-10-26 | Janssen Pharmaceutica Nv | Casein kinase 1 delta modulators |
US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
CN115466211B (en) * | 2022-06-09 | 2024-02-23 | 中国人民解放军空军军医大学 | N-phenylquinoline-4-amine compound and application thereof |
WO2024012554A1 (en) * | 2022-07-14 | 2024-01-18 | 上海日馨医药科技股份有限公司 | Tpk agonist and method for treating neurodegenerative diseases using same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012497A2 (en) * | 1998-08-28 | 2000-03-09 | Scios Inc. | Quinazoline derivatives as medicaments |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US5545656A (en) * | 1995-04-05 | 1996-08-13 | Pfizer Inc. | 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease |
US20030219427A1 (en) * | 1998-08-18 | 2003-11-27 | Allen Hamish J. | TPL-2/COT kinase and methods of use |
US6087363A (en) * | 1999-07-16 | 2000-07-11 | Harbor Branch Oceanographic Institution, Inc. | Use of imidazole and indole compounds as inhibitors of nitric oxide synthase |
WO2002018386A1 (en) * | 2000-09-01 | 2002-03-07 | Sanofi-Synthelabo | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES |
DE60128709T2 (en) * | 2000-09-15 | 2007-12-27 | Vertex Pharmaceuticals Inc., Cambridge | TRIAZOL COMPOUNDS AS PROTEIN KINASE INHIBITORS |
US7045539B2 (en) * | 2000-12-22 | 2006-05-16 | Astrazeneca Ab | Therapeutic benzoxazole compounds |
AU2002359714B2 (en) * | 2001-12-18 | 2006-12-21 | Merck Sharp & Dohme Corp. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
JP2003212859A (en) * | 2002-01-24 | 2003-07-30 | Nippon Nohyaku Co Ltd | Substituted phenylheterocycles and herbicide containing the same as active ingredient |
EP1487822B1 (en) * | 2002-03-08 | 2007-08-01 | Eli Lilly And Company | Pyrrole-2,5-dione derivatives and their use as gsk-3 inhibitors |
FR2836915B1 (en) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | AMINOINDAZOLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
WO2003097615A1 (en) * | 2002-05-17 | 2003-11-27 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS |
WO2003106439A1 (en) * | 2002-06-12 | 2003-12-24 | 株式会社ビーエフ研究所 | Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation |
CL2004000409A1 (en) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | COMPOUNDS DERIVED FROM 2- (REPLACED CILO) -1- (AMINO OR REPLACED OXI) -CHINAZOLINE, INHIBITORS OF IONIC SODIUM AND CALCIUM VOLTAGE DEPENDENTS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF ACUTE PAIN, CHRONIC, NEU |
US7060698B2 (en) * | 2003-05-19 | 2006-06-13 | Hoffmann-La Roche Inc. | Benzoxazepinone derivatives |
WO2005000405A2 (en) * | 2003-06-06 | 2005-01-06 | The Trustees Of The University Of Pennsylvania | P38 kinase inhibitor compositions and methods of use |
GB0314943D0 (en) | 2003-06-25 | 2003-07-30 | Proteome Sciences Plc | Screening methods |
US7560464B2 (en) * | 2004-04-13 | 2009-07-14 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
ATE445396T1 (en) * | 2004-08-19 | 2009-10-15 | Aventis Pharma Inc | 3-ARYLTHIOINDOLE-2-CARBONIC ACID AMIDE DERIVATIVES AND THEIR ANALOGUES AS INHIBITORS OF CASEINKINASE I |
WO2007015866A2 (en) * | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
EP1842541A1 (en) * | 2006-03-29 | 2007-10-10 | G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg | Plant components and extracts and uses thereof |
TW200813035A (en) * | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
CA2652859A1 (en) * | 2006-06-21 | 2007-12-27 | E.I. Du Pont De Nemours And Company | Pyrazinones as cellular proliferation inhibitors |
US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
KR101176700B1 (en) * | 2006-11-02 | 2012-08-23 | 에프. 호프만-라 로슈 아게 | Substituted 2-imidazoles as modulators of the trace amine associated receptors |
US8362066B2 (en) * | 2006-11-17 | 2013-01-29 | Treventis Corporation | Compounds and methods for treating protein folding disorders |
EP2125683B1 (en) * | 2006-12-19 | 2013-10-23 | The Board of Trustees of the University of Illinois | 3-benzofuranyl-4-indolyl-maleimides as potent gsk-3 inhibitors for neurodegenerative disorders |
WO2008156715A1 (en) * | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Cetp inhibitors derived from benzoxazole arylamides |
FR2918061B1 (en) * | 2007-06-28 | 2010-10-22 | Sanofi Aventis | 6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO-1,2-B1-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
FR2918986B1 (en) * | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | 6-CYCLOAMINO-3- (PYRIDAZIN-4-YL) IMIDAZO [1,2-B] -PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
GB0715939D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
AU2008331854A1 (en) * | 2007-11-28 | 2009-06-11 | Yale University | Nogo receptor binding small molecules to promote axonal growth |
CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
EP2149551A1 (en) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors |
FR2934994B1 (en) * | 2008-08-12 | 2010-09-17 | Sanofi Aventis | DERIVATIVES OF 2-ALKYL-6CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZ-1,2-B! PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
KR101257695B1 (en) * | 2008-12-24 | 2013-04-24 | 제일모직주식회사 | Novel compound for organic photoelectric device and organic photoelectric device including the same |
FR2945289A1 (en) * | 2009-05-11 | 2010-11-12 | Sanofi Aventis | 2-CYCLOAMINO-5- (PYRIDIN-4-YL) IMIDAZO-2,1-B1 DERIVATIVES 1,3,4! THIADIAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
MX2012008346A (en) * | 2010-01-25 | 2012-11-12 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. |
CN104906103B (en) * | 2010-12-14 | 2018-05-18 | 电泳有限公司 | Casein kinase 1 δ (CK1 δ) inhibitor |
CN103842362B (en) | 2011-05-09 | 2017-05-24 | 爱普制药有限责任公司 | Compositions and methods for treating Alzheimer's disease |
-
2011
- 2011-12-14 CN CN201510246272.4A patent/CN104906103B/en not_active Expired - Fee Related
- 2011-12-14 EP EP11804754.7A patent/EP2651404B1/en not_active Not-in-force
- 2011-12-14 EP EP11804755.4A patent/EP2651405A2/en not_active Withdrawn
- 2011-12-14 ES ES11804754.7T patent/ES2553610T3/en active Active
- 2011-12-14 ES ES14190691.7T patent/ES2650744T3/en active Active
- 2011-12-14 JP JP2013543879A patent/JP5937102B2/en not_active Expired - Fee Related
- 2011-12-14 AU AU2011343039A patent/AU2011343039B2/en not_active Ceased
- 2011-12-14 DK DK14190691.7T patent/DK2835131T3/en active
- 2011-12-14 US US13/993,303 patent/US20140018540A1/en not_active Abandoned
- 2011-12-14 US US13/993,288 patent/US20140031547A1/en not_active Abandoned
- 2011-12-14 WO PCT/GB2011/052473 patent/WO2012080727A2/en active Application Filing
- 2011-12-14 JP JP2013543881A patent/JP2014503528A/en active Pending
- 2011-12-14 CN CN201180060132.8A patent/CN103298460B/en not_active Expired - Fee Related
- 2011-12-14 CN CN201610264700.0A patent/CN105920010A/en active Pending
- 2011-12-14 EP EP14190691.7A patent/EP2835131B1/en not_active Not-in-force
- 2011-12-14 WO PCT/GB2011/052475 patent/WO2012080729A2/en active Application Filing
- 2011-12-14 CA CA2818903A patent/CA2818903C/en active Active
-
2014
- 2014-04-22 HK HK14103807.1A patent/HK1190622A1/en not_active IP Right Cessation
-
2015
- 2015-04-02 US US14/677,273 patent/US9789111B2/en active Active
- 2015-09-01 US US14/842,155 patent/US9763947B2/en active Active
-
2016
- 2016-03-07 HK HK16102571.5A patent/HK1214527A1/en unknown
- 2016-05-11 JP JP2016095027A patent/JP6243472B2/en active Active
- 2016-06-02 US US15/171,582 patent/US20160354375A1/en not_active Abandoned
- 2016-09-08 JP JP2016175298A patent/JP2017025080A/en not_active Withdrawn
-
2017
- 2017-02-06 AU AU2017200812A patent/AU2017200812B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012497A2 (en) * | 1998-08-28 | 2000-03-09 | Scios Inc. | Quinazoline derivatives as medicaments |
Non-Patent Citations (1)
Title |
---|
Flajolet, M., et al. âRegulation of Alzheimerâs disease amyloid-β formation by casein kinase I." PNAS. (March 6, 2007), Vol. 104, No. 10, pp. 4159-4164. * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11084807B2 (en) | 2016-08-18 | 2021-08-10 | Vidac Pharama Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
US11673894B2 (en) | 2018-02-27 | 2023-06-13 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
US11873304B2 (en) | 2018-05-18 | 2024-01-16 | Incyte Corporation | Fused pyrimidine derivatives as A2A/A2B inhibitors |
US11161850B2 (en) | 2018-07-05 | 2021-11-02 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
WO2020051206A1 (en) * | 2018-09-04 | 2020-03-12 | Brown University | Compositions and methods for the modulation of crfbp and the treatment of alcoholism |
US11278527B2 (en) | 2018-09-04 | 2022-03-22 | Brown University | Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder |
US11390624B2 (en) | 2019-01-29 | 2022-07-19 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
US11884665B2 (en) | 2019-01-29 | 2024-01-30 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
US11613548B2 (en) | 2021-02-19 | 2023-03-28 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160354375A1 (en) | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | |
US11155561B2 (en) | Substituted glutarimides as Btk inhibitors | |
US8013153B2 (en) | Substituted pyrimidine kinase inhibitors | |
US7338966B2 (en) | Substituted oxindole derivatives as tyrosine kinase inhibitors | |
KR100823382B1 (en) | FAB I Inhibitors | |
RU2637936C2 (en) | Inhibitors of lrrk2 kinases activity | |
US20190194207A1 (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
US20060293343A1 (en) | Pyrimidine derivatives | |
TWI612034B (en) | Indole carboxamide derivatives as p2x7 receptor antagonists | |
US20170037044A1 (en) | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | |
US20150152088A1 (en) | Alkynyl heteroaromatic compound and use thereof | |
US20080293785A1 (en) | Substituted benzothiazole kinase inhibitors | |
CN112189012B (en) | Trisubstituted aryl and heteroaryl derivatives as modulators of PI3 kinase and autophagy pathways | |
US9527850B2 (en) | Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist | |
CN111406054A (en) | 1, 2, 4-oxadiazole derivatives as inhibitors of histone deacetylase 6 | |
JP2004508366A (en) | Oxindole derivatives | |
JP7144863B2 (en) | Isoquinoline compounds, methods for their preparation, and their therapeutic use in conditions associated with altered activity of beta-galactosidase | |
CN114075140A (en) | Pyrazole amide derivatives as EP4 receptor antagonists and their use in cancer and inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ELECTROPHORETICS LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHERIDAN, JOSEPH M.;HEAL, JONATHAN R.;HAMILTON, WILLIAM D.O.;AND OTHERS;REEL/FRAME:038787/0830 Effective date: 20130902 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |